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 IL-10 is a non-redundant inflammatory modulator that suppresses the 
development of arthritis in Borrelia burgdorferi infected mice.  Previous microarray 
studies of infected B6 and C3H joint tissue found IL-10 to be induced only in B6 mice, 
leading to the hypothesis that the inability to produce IL-10 was a factor in arthritis 
development in C3H mice.  Expression of IL-10 was robust in the skin from around the 
ankle joint in both B6 and C3H mice, suggesting that arthritis in C3H mice develops 
through pathways not regulated by IL-10.   
B6 IL-10-/- mice were previously found to have a robust and sustained interferon-
inducible response in joint tissues, and the current study identified high concentrations of 
IFN-γ in sera.  Infection of IL-10 reporter mice demonstrated that macrophages and CD4+ 
T cells were the primary sources of IL-10 in the infected joint and skin tissues, which 
suggested that early local production of IL-10 dampened the pro-arthritic interferon 
response.  In fact, treatment of IL-10-/- mice with anti-IFN-γ reduced arthritis severity and 
suppressed interferon-inducible transcripts to wild type levels, thereby linking 
dysregulation of IFN-γ to disease in the IL-10-/- mouse.  Arthritis in IL-10 deficient mice 
was associated with elevated numbers of NK cell, NKT cell, α/β T cell, and macrophage 
infiltration of the infected joint.  FACS lineage sorting revealed NK cells and CD4+ T 
cells as sources of IFN-γ in the joint tissue of IL-10-/- mice.  These findings suggest the 
presence of a positive feedback loop in the joint tissue of infected IL-10-/- mice, where 
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production of inflammatory chemokines, infiltration of IFN-γ producing cells, and 
additional production of inflammatory cytokines result in arthritis.  This mechanism of 
arthritis is in contrast to that seen in C3H mice, where arthritis development is linked to 
transient production of Type I interferon, and develops independently of IFN-γ.  Due to 
the sustained interferon response driven by NK cells and T cells, we propose the IL-10-/- 
mouse as a potential model to study the prolonged symptoms observed in some human 
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Lyme Disease 
 
Lyme borreliosis (also termed Lyme disease) is the manifestation of one or more 
lesions that result following infection with the tick-borne spirochetes Borrelia 
burgdorferi, Borrelia afzelii, and Borrelia garinii (1-3).  These three species have been 
documented in Europe and Asia, and are collectively termed Borrelia sensu lato.  
Borrelia burgdorferi is the only species found in North America, and therefore the term 
‘sensu strico’ is added to the end of the species name.  Whether in Europe or North 
America, these bacteria are transmitted through the bite of hard-bodied ticks of the Ixodes 
genus (2, 3).  In the U.S., there are up to 30,000 new cases of Lyme disease reported each 
year, making it the most common vector-transmitted infection in America. 
Lyme disease was initially misdiagnosed as ‘juvenile rheumatoid arthritis’ in 
children, and ‘early onset rheumatoid arthritis’ in adults, which was sometimes preceded 
by a characteristic rash (4).  The high prevalence of these conditions in Lyme, 
Connecticut suggested environmental factors were the cause of these syndromes.  It was 
not until 1982, when Burgdorfer et al discovered a new species of Borrelia present in 
Long Island Ixodes tick populations that was recognized by patients’ sera that a 
connection could be made (3).  Shortly after this discovery, two independent groups 
isolated these newly identified spirochetes from Lyme disease patients, establishing these 
aptly named (Borrelia burgdorferi) spirochetes as the causative agent of Lyme disease 
(2, 5). 
Several days after tick inoculation, most patients develop a hallmark ‘bulls eye’ 
rash, termed ‘erythema migrans’, at the site of the tick bite.  This rash is thought to result 
from the localized innate immune response to disseminating spirochetal migration into 
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the dermal microvasculature (6, 7).  In the absence of appropriate antibiotic therapy, the 
bacteria will disseminate from the site of inoculation hematogenously, and case a 
systemic infection (6).  At this temporal point of infection, patients experience what are 
termed ‘early’ symptoms, which include fever, fatigue, body aches, and general malaise 
(8, 9).  Disseminating spirochetes infect multiple tissues, but preferentially invade 
secondary skin sites, nervous tissue, cardiac tissue, and connective tissue of the joint, and 
cause disease several months after the initial infection (2, 10-12).  
 
Lyme Arthritis 
Arthritis is the most common late stage symptom associated with B. burgdorferi 
infection, with up to 60% of untreated individuals developing Lyme arthritis (13, 14).  In 
addition, up to 30% of individuals who receive treatment will go on to develop arthritis.  
This self-limiting, infection-associated arthritis is intermittent if untreated, and typically 
affects only one large joint, though multiple joints may be affected over the course of 
infection (14-16).  This Lyme arthritis is characterized by swelling, edema, 
hyperproliferation of the synovium, and a moderate inflammatory infiltrate that consists 
primarily of granulocytes (15, 17, 18).  Excluding patients who develop no adverse 
effects from B. burgdorferi infection, the severity of arthritis varies greatly among 
untreated individuals, ranging from subjective joint pain, to intermittent attacks of 
arthritis, to chronic erosive disease (14).  The range in arthritis severity observed in 
humans may be due to the genetic propensity for arthritis development in the host, the 
arthritic potential of the infecting B. burgdorferi strain, or a combination of both. 
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Antibiotic-Refractory Lyme Arthritis 
Most human patients with Lyme arthritis and other late stage symptoms respond 
to antibiotic therapy, after which arthritis eventually resolves (19).  However, in some 
cases arthritis persists for many months after treatment designed to eradicate infection, 
suggesting that there is a subset of individuals that maintain a long-term inflammatory 
response in the absence of active infection (19, 20).  This condition has been termed 
“antibiotic-refractory Lyme arthritis” and more recently recognized as “Post-treatment 
Lyme disease” (21, 22).  Genetic population studies identified several MHC class II 
alleles that were associated with antibiotic-refractory Lyme arthritis patients, which led to 
a hypothesis that this chronic condition was the result of T cell cross-reactivity with B. 
burgdorferi antigens and self antigens found in the host joint tissue (19, 23, 24).  The 
alleles identified, HLA-DRB1*0401, HLA-DRB1*0101, and HLA-DRB1*0404 have 
also been associated with rheumatoid arthritis susceptibility (24-27).  The identification 
of a peptide from the B. burgdorferi lipoprotein, outer surface protein A (OspA), had 
sequence homology to the human protein LFA-1, further supported this idea (25).  The 
LFA-1 peptide bound to HLA-DRB1*0401, and some patients had T cells that reacted to 
the OspA peptide presented by this allele.  Thus the link to autoimmunity was proposed 
to result from patient T cell cross reactivity between two similar peptides derived from 
two interspecies proteins (25).  Subsequent studies examining T cell receptor promiscuity 
found that cross reactivity was common, and that epitope mimicry was not robust 
evidence for autoimmune disease (28).  In addition to autoimmunity, other less studied 
hypotheses exist to explain the development of antibiotic-refractory Lyme arthritis.  One 
of these hypotheses is that the local immune response in the joint to the invading 
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spirochetes is poorly regulated and results in sustained inflammation in the synovium 
(19).  Interestingly elevated levels of IFN-γ, and extremely high levels of the T cell, NK 
cell, and monocyte recruiting chemokines CXCL-9 and CXCL-10, are found in patients 
with antibiotic-refractory Lyme arthritis when compared to patients with antibiotic-
responsive Lyme arthritis (20).  Additionally, recent data have shown that certain B. 
burgdorferi isolates are capable of inducing more robust immune responses than other 
conventional strains (29). Thus, it is unclear why Post-Treatment Lyme Disease patients 
are genetically susceptible. 
 
Borrelia burgdorferi 
Borrelia burgdorferi are classified as spirochetes, due to their characteristic, 
corkscrew-like shape.  These bacteria are 0.2-0.5µM in diameter, and 10-30µM in length 
and contain periplasmic flagellae, which make these bacteria extremely motile (30).  B. 
burgdorferi are morphologically similar to classic gram-negative organisms; however, 
they lack the biosynthetic pathways required for synthesis of lipopolysacharide (LPS), a 
feature that was accepted based on early biochemical and functional studies prior to 
publication of the B. burgdorferi genome sequence (31-34).  Rather than LPS, these 
spirochetes have abundant tripalmitoyl-S-glyceryl-cystein (Pam3Cys) lipoproteins on 
their surface.  Genes encoding more than 150 putative lipoproteins possessing the signal 
peptidase II sequence are found in the B. burgdorferi chromosomal genome, and which 
render them particularly immunogenic (34-37).  Two strains of B. burgdorferi, N40 and 
B31, are routinely used in the laboratory, and were both isolated from ticks in Long 
Island (3, 38).  Both strains contain multiple linear and circular plasmids, some of which 
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are essential for bacterial survival, and some of which contain virulence factors (39-41).  
The complex ‘organization’ of the B. burgdorferi genome has made it difficult to identify 
bacterial mechanisms of virulence (39). 
The life cycle of B. burgdorferi is dependent on its ability to infect its mammalian 
host, and persist within both the tick vector and the mammalian host.  Larval Ixodes 
scapularis ticks hatch from eggs in the spring, and acquire the infection from a 
previously infected rodent, rendering the tick infectious for life.  The following spring, 
the ticks, now in the nymphal stage, acquire their second blood meal, likely from a 
rodent.  It is this cycle of larval acquisition, and nymphal transmission that propagates the 
bacteria.  After nymphal ticks acquire their blood meal, they molt and mature to adult 
ticks.  The adult ticks acquire a final blood meal from white-tailed deer, mate, lay non-
infectious eggs, and die (42).  Thus, due to its complex life cycle, B. burgdorferi must 
persist within its mammalian host for an entire year.  One such mechanism by which B. 
burgdorferi persist is to alter the expression of dominant surface lipoproteins to avoid the 
host adaptive immune response (43).  The gene for one such immuno-dominant B. 
burgdorferi lipoprotein, vlsE, is found on a plasmid associated with 15 silent “vamp-like 
sequences” or cassettes, portions of which re-combine with a central, upstream VlsE 
expression cassette to generate an altered surface lipoprotein through gene conversion 
(44, 45).  Taking into account the duration required for a host antibody response, and the 
millions of possible combinations of VlsE, B. burgdorferi spirochetes are capable of 
persisting in their hosts for the lifetime of the host organism.   
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Mouse Models of Lyme Arthritis 
Animal models of Lyme disease, particularly mouse models, are a powerful tool 
in elucidating the pathogenesis of B. burgdorferi.  In nature, mice and other rodents are 
the primary reservoir of these bacteria, and are therefore a logical choice for disease 
modeling.  Currently, no murine model of neuroborreliosis or Post-Treatment Lyme 
Disease exists that accurately models these conditions.  The acute, infection-associated, 
Lyme arthritis, however, has accurately been modeled using the C3H/He (C3H), BALB/c 
and C57BL/6 inbred mouse strains.  Unlike human rheumatoid arthritis, murine Lyme 
arthritis is an inflammatory arthritis that is induced by a known, and natural trigger.  The 
process of arthritogenesis can therefore be monitored from beginning, and the identified 
mechanisms will likely provide insight into general features of many arthritic diseases.  
Many of the symptoms associated with B. burgdorferi infection in human are similar in 
these mice, and the Lyme arthritis phenotypes found among these strains represent a 
range in arthritis phenotypes, modeling the spectrum in disease severity seen in humans 
(46).  In infection models that utilize intradermal needle inoculation, spirochetes reach 
the joint by 1 week of infection, and achieve maximal density at two weeks after 
infection, while arthritis develops 3-4 weeks after infection (47-49).  Although arthritis 
develops in multiple joints, it is most prominently seen in the tibiotarsal (ankle) joints 
(46).  In C3H mice, arthritis is severe, with robust infiltration of neutrophils along with 
the accumulation of edema in the tibiotarsal joint, joint space, and contiguous supportive 
tissues, as well as proliferation of synoviocytes of the tibiotarsal tendon sheath (46, 47).  
These lesions have also been observed in B6 mice, but the severity of disease is greatly 
decreased in comparison (46, 48).  Interestingly, arthritis development in BALB/c mice is 
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dependent on the inoculum dose, where mice infected with a low number of spirochetes 
develop mild arthritis, but severe arthritis is observed at higher inoculum dose (46).  The 
range in arthritis severity between B6 and C3H mice is not due to a failure of one strain 
to adequately manage the infection, as both strains harbor similar numbers of joint 
spirochetes, suggesting that the type of host immune response, the magnitude of this 
response, and/or the regulation of this response is genetically regulated (48).  
 
The Host Response to B. burgdorferi 
Cells of both the innate and adaptive immune system play critical roles in the 
control of B. burgdorferi infection, although it should be noted that the host immune 
system alone is incapable of sterile clearance of these spirochetes (50-52).  During the 
early stages of B. burgdorferi infection, multiple cells of the innate immune system are 
activated, including macrophages, neutrophils, and NK cells (53-56).  The early and 
robust immune response to B. burgdorferi is thought to be due, in part, to the abundant 
lipoproteins found on the surface of these spirochetes, which are recognized by Toll like 
receptor 2 (TLR2) (57-59).  The B. burgdorferi genome encodes approximately 150 
putative lipoproteins (34).  Recognition of these lipoproteins by cells of the innate 
immune system ultimately results in the activation of NF-κB, and the production of both 
pro- and anti-inflammatory cytokines thought to modulate the development of Lyme 
arthritis (53, 57, 60).  Mice lacking TLR2 harbor 10-fold more bacteria in their joints than 
do WT mice, and mice lacking the common TLR adapter molecule MyD88 harbor 100-
fold more bacteria than their WT littermates (61, 62).  This indicates that there are 
MyD88 dependent pathways that participate in immune clearance of B. burgdorferi that 
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are independent of TLR2.  Interestingly, arthritis severity in TLR2-/- mice, on both the 
C3H and B6 backgrounds is greater than in WT mice of the same strain (61, 63, 64). In 
addition, because arthritis development was not halted in the absence of TLR-2, 
additional pathways must exist that may be involved in bacterial recognition.  This will 
be further discussed below.   
It is still largely unknown how innate immune cells kill B. burgdorferi in vivo, 
however, multiple cell types, particularly those of myeloid lineage, including microglia, 
have been reported to kill B. burgdorferi in vitro (65-67).  Macrophages but not 
neutrophils are capable of phagocytosing B. burgdorferi in the absence of opsonizing 
antibody in vitro (56, 68).  This may emphasize an important early role played by 
macrophages in host defense.  Interestingly, killing of B. burgdorferi by human PMN in 
vitro is more efficient when the neutrophils are lysed (69).  Calprotectin, a protein found 
abundantly within these lysates was found to account for a portion of this activity.  
Interestingly, both historic and contemporary finding have demonstrated the anti-
microbial properties of host histone molecules as well as neutrophil extracellular traps 
(NET), which may account for the remainder of this killing activity (70-72).  It is widely 
held that reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
bactericidal.  However, the viability of B. burgdorferi is not altered when subjected to 
hydrogen peroxide and other oxidative stresses (73).  Additionally, B. burgdorferi–
infected mice lacking either iNOS, or essential components of the NADPH oxidase 
pathway are not impaired in their ability to control infection (74-76).  This is partially 
explained by the fact that B. burgdorferi does not use free iron or iron-bound enzymes, 
which are sensitive to reactive oxygen species (77).   
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The adaptive immune response, particularly the B cell response is critical in the 
management of B. burgdorferi infection.  The fact that arthritis develops in the absence of 
T and B lymphocytes in C3H mice has often overshadowed the observation that arthritis 
fails to resolve without these cells (78-80).  Mice that lack B and T cells, or are deficient 
in antibody production have elevated levels of B. burgdorferi in their tissues, and this 
defect can be ameliorated by passive transfer of human immune sera and B cells (81-83).  
Interestingly, B. burgdorferi and their lipoproteins act as potent B cell mitogens, that 
stimulate polyclonal activation of these cells through TLR2-dependent and independent 
pathways (60, 84).  A consequence of this polyclonal proliferation of B cells in infected 
individuals is the development of lymphoadenopathy (swollen lymph nodes).  Only a 
fraction of the antibody produced by these proliferating B cells is antigen specific, and 
this may be a mechanism used by the bacteria to confound its host (84, 85).  
 
T cell Polarity in Lyme Arthritis 
Early histopathological studies from human Lyme disease patients proposed that 
T cells were directly involved in tissue damage that results in arthritis (6).  These findings 
prompted the examination of T cell polarity, particularly the TH1 polarized T cell subset, 
as the culprits that lead to Lyme arthritis development (86).  Indeed, a study examining 
arthritis development in the susceptible C3H strain injected with neutralizing antibody to 
IFN-γ (a pro-inflammatory TH1-associated cytokine) showed that ankle swelling was 
reduced following this treatment (87).  Another set of studies, seeking to show that 
arthritis could be exacerbated in the absence of IL-4 (a cytokine that restricts 
development of TH1 T cells), demonstrated that arthritis was exacerbated in the normally 
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arthritis-resistant BALB/c strain, and also showed that addition of exogenous IL-4 
resulted in reduced arthritis severity in C3H mice (88, 89).  However, subsequent studies 
using gene-targeted knockout mice for IFN-γ (on the C3H background), IL-4, and IL-
4/IL-13 receptor on the DBA (arthritis resistant) B6, or BALB/c background did not 
confirm these studies (90, 91).  One explanation for the discrepancy in the study utilizing 
recombinant IL-4 in C3H mice is that the authors examined resolution, rather than 
development of Lyme arthritis.  A second, and perhaps more telling, reason for the 
discrepancy between all of these experiments is that the former experiments, utilizing 
neutralizing antibody and recombinant proteins failed to examine the histopathological 
evidence of arthritis.  The edema associated with Lyme arthritis is responsible for 
increased ankle swelling, but contains a sparse inflammatory infiltrate, and may or may 
not be an indicator of joint inflammation (92, 93).  A final study utilizing C3H scid mice 
(these mice have no B or T cells) authoritatively demonstrated that these mice develop 
severe arthritis, despite the lack of T cells (78).  Because arthritis develops in the absence 
of TH1 polarity, the role of these polarized CD4+ T cells, as well as the cytokine, IFN-γ 
remains elusive in mice and little can be extrapolated to human disease.  The apparent 
lack of T cell involvement in the C3H model of Lyme arthritis appears contradictory to 
what has been reported in human patients, and reflects another possible weakness of the 
murine Lyme arthritis model.  This issue will further be discussed in Chapter 2.   
 
Development of Inflammatory Lyme Arthritis 
The development of Lyme arthritis is preceded by spirochetal invasion of the 
joint, and this event is thought to be required for arthritis development (33, 94).  In mice, 
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invasion begins at 7 days of infection, and at 14 days of infection, bacterial numbers in 
the joint reach their highest levels (47).  In the arthritis susceptible C3H mice, but not in 
the arthritis-resistant B6 mice, the PMN and monocyte recruiting chemokines, CXCL-1 
and CCL-2 were found to be at their highest levels 4 days prior to, and at the peak of 
arthritis severity (95).  By histopathological examination of infected joint tissue, the 2-
week time point is also when a myeloid infiltrate, consisting of primarily of granulocytes, 
but also includes monocytes and macrophages, is detected, and is more prominent in C3H 
mice than in B6 mice (46, 47).  C3H mice lacking the chemokine receptor, CXCR2 
(receptor for KC), but not mice deficient for CCR2 (receptor for MCP-1) developed 
reduced arthritis severity (95, 96).  This suggests that prior to arthritis development, B. 
burgdorferi induce expression of these chemokines in local joint cells, which ultimately 
results in arthritis development in C3H mice.  The fact that both the arthritis susceptible 
(C3H) and arthritis resistant (B6) strains harbor similar numbers of spirochetes in their 
joint tissue, and therefore similar stimulation potential for the production of the above 
chemokines, suggests arthritogenic mechanisms are genetically controlled (48).  Indeed 
genetic linkage analysis of B6 and C3H intercross populations revealed the presence of 
multiple quantitative trait loci (QTL), two of which reciprocally transfer the severe 
arthritis phenotype, located on mouse chromosomes 5 and 11 (75, 93, 97). 
In an effort to understand the mechanism(s) underlying the development of Lyme 
arthritis, microarray analyses were performed on infected joint tissue from C3H and B6 
mice at 1, 2, and 4 weeks of infection with B. burgdorferi (98).  A striking feature of this 
experiment was that, at the earliest time point after infection in the arthritis susceptible 
C3H mouse, there was evidence of a robust interferon-inducible response that was absent 
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in the arthritis-resistant B6 mice (98).  Because this interferon-induced response was 
correlated to severe arthritis development in C3H mice, and others had reported that C3H 
IFN-γ-/- mice retain the severe arthritis phenotype, it was hypothesized that type I 
interferon may have a role in promoting Lyme arthritis development in C3H mice (90, 
98).  Indeed, C3H mice injected with antibody that prevents signaling through the Type I 
interferon receptor had reduced ankle swelling and overall lesion development compared 
to C3H mice receiving control treatments (99).  Interestingly, a dissection of the 
interferon-induced response in the joints of infected C3H mice demonstrated that Type I 
interferon was only partially responsible for the induction of interferon-responsive genes.  
In fact, the most robustly induced transcripts appeared to be due to NK cell-derived IFN-γ 
(99).  To circumvent this complicating issue, bone marrow derived macrophages 
(BMDM), which do not produce IFN-γ, from multiple gene knockout mouse strains were 
utilized to identify the pathways that induce Type I interferon production.  It was found 
that induction of Type I interferon was independent of TLR2, TLR4, TLR9, and MyD88, 
but was dependent on feedback through the Type I interferon receptor (99).  Similar 
findings in human peripheral blood mononuclear cells (PBMC’s) suggested that B. 
burgdorferi have the capacity to enact this pathway in human Lyme disease (100).  Later 
findings in BMDM revealed this feed-forward loop to be dependent on IRF-3, and 
additionally identified B. burgdorferi RNA as a ligand that is capable of inducing a Type 
I interferon response (101).  Finally, two independent groups demonstrated that 
production of both IFN-α and IFN-β in human mononuclear cells was reduced when cells 
were pretreated with inhibitors of TLR-7, TLR-8, and TLR-9, receptors that recognize 
microbial RNA and CpG DNA (102-104).  Petzke et al. also demonstrated that 
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plasmacytoid dendritic cells (pDC) produced Type I interferon in response to B. 
burgdorferi stimulation, an observation not observed in purified murine pDC’s (99, 102).  
Interestingly, in the heterogeneous PBMC population, expression of Type I interferon 
was relatively modest when compared to the robust induction of IFN-γ (100, 102).  This 
observation indicates that the induction of IFN-γ may overshadow the contribution of 
Type I interferon in the human interferon response.  
In addition to the robust interferon response observed by microarray at 1 week of 
infection, both strains of mice displayed hallmark transcripts of the immune response at 2 
weeks of infection, characteristic of immune cell infiltration, as well as the including 
chemokines in both the arthritis-susceptible and arthritis-resistant strain (98).  At both 2 
and 4 weeks of infection, during the peak of arthritis severity in C3H mice, hallmark 
transcripts previously associated with the murine collagen induced arthritis model were 
apparent (98, 105).  Of these genes, matrix-metalloproteinases (MMP) were of particular 
interest, as they are thought to be the cause cartilage and bone destruction.  MMP-3 was 
induced in both strains of mice, while MMP-9 was seen only in C3H mice at 2 weeks of 
infection.  C3H mice deficient in MMP-9 display reduced arthritis severity, but 
unchanged bacterial numbers (106).  Interestingly, MMP-3, but not MMP-9 was 
predominant in the synovial fluids of patients with acute Lyme arthritis, while MMP-9 
was more prominent in synovial fluids of antibiotic-refractory Lyme arthritis patients 
(107).   
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Expression and Function of Interleukin-10 
Interleukin-10 (IL-10) is a nonredundant, pleiotropic, anti-inflammatory cytokine, 
whose primary effects are on macrophages and monocytes (108-110).  Although IL-10 
was initially shown to act on T cells and NK cells, the majority of these mechanisms have 
shown to be indirect (108).  IL-10 enacts its suppressive activity by inducing the release 
of soluble receptors for some pro-inflammatory cytokines, reducing expression of MHC 
class II and co-stimulatory molecules, inducing instability of pro-inflammatory cytokine 
and chemokine mRNA, and induces expression of TIMP (Tissue inhibitor of matrix 
metalloproteinase) (108-114).  Multiple cell types, including CD4+ and CD8+ T cell 
subsets, dendritic cells, macrophages, B cells, and keratinocytes have been reported as 
sources of this cytokine (115).   IL-10 was originally found to be a TH2-associated 
cytokine, but it is now understood that all known CD4+ T cell subsets are capable of 
producing this cytokine (116).  Production of IL-10 by TH1, TH2, and TH17 subsets 
require the identical signals needed for differentiation and the activation of ERK, which 
is thought to come from IL-21 and/or IL-27.  Additionally, TH1, TH2, and TH17 cells 
require activation of STAT4, STAT6, and STAT3, respectively, for optimal IL-10 
expression (116).  The signals that induce IL-10 expression in regulatory T cells are 
largely unknown.  In myeloid lineage cells, induction of IL-10 utilizes TLR signaling 
through MyD88 and/or TRIF, which activate signaling molecules such as ERK and p38.  
This ultimately allows transcription factors such as CREB, SP1, SP3, C/EBP and NF-κB 
to associate with enhancer sequences in the IL-10 promoter (117-122).  Interestingly, T 
cells and myeloid-lineage cells each have a unique DNase I hypersensitivity site (HSS) 
within the IL-10 locus.  For T cells, this site is several KB downstream of the start site, 
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while the myeloid HSS is several KB upstream of the promoter region (116).  Thus, the 
mechanisms required for IL-10 expression differs greatly between cell types, and may 
reflect differences in both the duration and magnitude of the IL-10 response. 
 
Interleukin 10 in Lyme Arthritis 
 An initial, and intriguing observation made about IL-10 was that BMDM derived 
from arthritis resistant B6 mice stimulated with B. burgdorferi lipoproteins produced 
much higher levels of IL-10 than macrophages derived from arthritis-susceptible C3H 
mice (61, 123).  Inversely, C3H macrophages produced higher concentrations of the pro-
inflammatory cytokines IL-6 and TNF-α.  Further, B6 IL-10-/- mice infected with B. 
burgdorferi harbored 5-10 fold fewer spirochetes in their joint tissue, but developed more 
severe arthritis than WT mice (123).  Microarray analyses of infected joint tissue from B6 
IL-10-/- mice revealed a delayed (compared to C3H), but sustained induction of 
interferon-inducible transcripts that was correlated to an increase in arthritis severity (98).  
Although the initial comparison of B6 IL-10-/- mice and C3H mice was performed in the 
context of genes that were highly induced in C3H mice, further scrutiny revealed unique 
and/or robust induction of cytokines and chemokines (98).  Finally, the observation that 
IL-10 overexpression failed to reduce arthritis severity in C3H mice led to the hypothesis 
that arthritis in the IL-10-/- mouse developed by a distinct mechanism from that observed 
for C3H mice (124). 
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Preview of Thesis Research 
 This dissertation is based heavily on two observations made by microarray 
analyses of B. burgdorferi-infected joint tissue.  The first observation is that, in the 
absence of IL-10, there is a robust, and sustained induction of interferon-inducible genes, 
which is correlated to an increase in arthritis severity in B6 IL-10-/- mice.  The second 
observation is that IFN-γ is robustly expressed at both 2 and 4 weeks of infection.  The 
experiments described herein were designed with goal to 1: characterized the source of 
the anti-arthritic IL-10, and 2: test the hypothesis that sustained IFN-γ expression was the 
driving force for arthritis development in IL-10-/- mice.   
Prior to this study, the function of IFN-γ in Lyme arthritis development was 
largely unknown, as mouse models failed to see phenotypes related to the absence of this 
cytokine.  Over the course of these studies, a group with access to patients with Post-
Treatment Lyme Disease published an important paper that reported elevated levels of 
IFN-γ and extremely high levels of the chemokines, CXCL-9 and CXCL-10 in the 
synovial fluid of patients with antibiotic-refractory, but not antibiotic-responsive, patients 
(20).  Of the known mouse models of Lyme arthritis, only the IL-10-/- mouse has a similar 
phenotype.  Thus, the IL-10-/- mouse model may provide an opportunity to elucidate the 
role of IFN-γ in Lyme arthritis in humans.  A second set of publications from groups not 
studying Lyme disease identified loss of function alleles in the il10r1 gene (125, 126).  
Although this is not thought to be the cause of severe disease seen in some Lyme arthritis 
patients, the IL-10-/- mouse phenotype is relevant to human disease, and may also provide 
insight into the balance between insufficient and overwhelming inflammatory responses. 
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Abstract 
 
IL-10 is a nonredundant inflammatory modulator that suppresses the development 
of arthritis in Borrelia burgdorferi infected mice.  Infected IL-10-/- mice were previously 
found to have a robust and sustained interferon-inducible response in joint tissue, and 
elevated IFN-γ in sera.  Infection of IL-10 reporter mice demonstrated that macrophages 
and CD4+ T cells were the primary sources of IL-10 in the infected joint tissue, which 
suggested that early local production of IL-10 dampened the pro-arthritic interferon 
response.  In fact, treatment of IL-10-/- mice with anti-IFN-γ reduced the increase in 
arthritis severity and suppressed interferon-inducible transcripts to wild type levels, 
thereby linking dysregulation of IFN-γ to disease in the IL-10-/- mouse.  Arthritis in IL-10 
deficient mice was associated with elevated numbers of NK cell, NKT cell, α/β T cell, 
and macrophage infiltration of the infected joint.  FACS lineage sorting revealed NK 
cells and CD4+ T cells as sources of IFN-γ in the joint tissue of IL-10-/- mice.  These 
findings suggest the presence of a positive feedback loop in the joint tissue of infected 
IL-10-/- mice, where production of inflammatory chemokines, infiltration of IFN-γ 
producing cells, and additional production of inflammatory cytokines result in arthritis.  
This mechanism of arthritis is in contrast to that seen in C3H mice, where arthritis 
development is linked to transient production of Type I interferon, and develops 
independently of IFN-γ.  Due to the sustained interferon response driven by NK cells and 
T cells, we propose the IL-10-/- mouse as a potential model to study the prolonged 
symptoms observed in some human Lyme disease patients.   
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Introduction 
Lyme disease is the manifestation of one or more lesions that result following 
infection with the spirochete Borrelia burgdorferi (1), which is transmitted to humans 
and animals through the bite of infected Ixodes ticks (2-4).  These bacteria establish 
infections of skin, cardiac, nervous, and/or connective tissue of the joint (5), and can 
cause disease at these sites (4).  Lyme arthritis occurs in up to 60% of infected humans 
not treated early with antibiotics, and may develop months after the initial infection (6).  
This arthritis is characterized by swelling, edema and a moderate inflammatory infiltrate 
that consists primarily of granulocytes (7).  These symptoms and lesions can be recurrent 
if untreated (6-8).  Most human patients with Lyme arthritis respond to antibiotic therapy, 
after which the arthritis eventually resolves (5).  However, in some cases arthritis persists 
after treatment designed to eradicate infection suggesting that there is a subset of 
individuals that maintain a long-term inflammatory response in the absence of active 
infection (5, 9). 
The acute, infection-associated arthritis seen in humans has been modeled using 
inbred mice, in particular, the C3H/HeN (C3H) and C57BL/6 (B6) strains.  In mice 
infected intradermally, B. burgdorferi reach maximal numbers in the joint tissue at 2 
weeks post infection, and arthritis severity peaks at 4 weeks after infection (10-12).  
Genetic susceptibility to arthritis development is clearly illustrated in inbred mice, and is 
independent of spirochete numbers in the joint (11, 13, 14).  In C3H mice, arthritis is 
severe, with robust infiltration of neutrophils along with the accumulation of edema in the 
tibiotarsal joint, joint space, and contiguous supportive tissues, as well as proliferation of 
synoviocytes of the tibiotarsal tendon sheath (10, 13).  These lesions have also been 
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observed in B6 mice, but the severity of disease is greatly decreased in comparison (11, 
13).  Severe arthritis development in C3H mice has not consistently been linked to 
skewing of T cell responses, such as IFN-γ-producing TH1 cells (15-17), or a lack of TH2 
responses (18, 19), and in fact, arthritis in C3H scid mice is equivalent in severity to 
wildtype (WT)3 C3H mice (20).  Rather than a T cell driven disease, arthritis in C3H 
mice has been linked to the production of Type I interferon (21), MMP-9 (22), and 
chemokines that signal through CXCR2 (23), and is also regulated through the CD14 
pathway (24). 
Much insight has been gained from the C3H mouse models of Lyme arthritis, as 
these mice have a robust phenotype that accurately mimics many symptoms associated 
with Lyme borreliosis in humans.  However, the C3H mouse does not completely model 
the spectrum of pathology observed in human Lyme arthritis (6).  The apparent lack of T 
cell involvement in this mouse model appears contradictory to what is reported in some 
human patients (25), where both TH1 (26) and γ/δ (27, 28) T cells have been implicated.  
Indeed, this holds true for a select group of Lyme arthritis patients who experience 
persistent arthritis after appropriate antibiotic therapy.  It has been hypothesized that 
these long-lasting symptoms are due to one or more of the following: 1) autoimmunity, 2) 
persistent undetectable levels of infection, 3) persistence of bacterial antigens, or 4) 
dysregulated inflammatory responses (1).  Recent findings from Shin et al. demonstrated 
a possible dysregulated inflammatory response in patients with antibiotic-refractory 
arthritis, as synovial fluid from these individuals contained elevated concentrations of the 
cytokines IL-1β, IL-6, IFN-γ, and others, as well as extremely high concentrations of the 
chemokines CXCL-9 and CXCL-10 (9).   
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The C57BL/6 (B6) mouse model is a useful tool in the study of Lyme arthritis, as 
it is resistant to the development of severe disease.  Multiple gene-targeted knockouts are 
available on this background, and thus, the B6 model provides an opportunity to explore 
specific deficiencies of acute and chronic inflammatory responses and mediators that may 
exacerbate Lyme arthritis (29-35).  IL-10 deficiency in B6 mice is one such knockout 
model, and this deficiency results in increased arthritis severity, even with 5-10 fold 
fewer spirochetes in the joint tissues of infected mice (36).  Infection of IL-10-/- mice 
with a related spirochete, Borrelia turicatae also leads to increased disease severity but 
enhanced control of the pathogen (37).  Production of pro-inflammatory cytokines by 
murine immune cells stimulated with B. burgdorferi is regulated by IL-10 (38), and in 
fact, previous microarray analyses of infected joint tissue from B6 IL-10-/- mice revealed 
a sustained induction of the cytokines IL-1β, IL-6, and IFN-γ and chemokines CXCL-9, 
and CXCL-10 (39).   All of these pro-inflammatory transcripts showed no signs of 
resolution, as they all had increased expression at 4 weeks of infection compared to 
earlier measurements.  In fact, the most highly induced gene in IL-10-/- mice, CXCL-9, 
displayed >500 and >800 fold induction at 2 and 4 weeks of infection, respectively.  
These findings are strikingly similar to the cytokine and chemokine profiles observed by 
Shin et al., in the synovial fluid of patients with treatment-refractory Lyme arthritis (9).   
In the current study, we have extended our analysis of the B6 IL-10-/- mouse as a 
Lyme arthritis model resulting from a dysregulated inflammatory response to low levels 
of joint spirochetes.  We identify the pro-inflammatory cytokine IFN-γ as a primary 
target of IL-10 in the joint tissue of the normally arthritis resistant B6 mice, and 
determine that macrophages and CD4+ T cells in infected joint tissue are the primary 
	   	   	  35	  
sources of this regulatory cytokine.  Furthermore, we identify both NK cells and CD4+ T 
cells as the primary sources of IFN-γ in the infected joints of IL-10-/- mice.  We propose 
that disruptions of the delicate balance between pro and anti-inflammatory signaling in 
both innate and adaptive immunity result in unique patterns of lesions during B. 
burgdorferi infection of joint tissue.  Furthermore, the IL-10-/- mouse provides an 
opportunity to dissect inflammatory events that are normally highly regulated, and result 
in pathological development when this balance is disrupted. 
 
Materials and Methods 
Mice, infections, and assessment of arthritis severity 
C57BL/6 (B6), B6.129P2-IL-10tm1Cgn/J (IL-10-/-), (B6.129S6-Il10tm1Flv/J (tiger), 
mice were purchased from The Jackson Laboratories.  B6-LY5.2/Cr (Ly5.1+) congenic 
mice were purchased from NCI.  All mice were housed in the University of Utah Animal 
Research Center (Salt Lake City, UT) and strict adherence to institutional guidelines were 
followed.  To avoid colitis development, IL-10-/- mice were kept on antibiotic water 
(trimethoprim and sulfamethoxazole) until one day prior to infection.  Mice were infected 
with 2×104 bacteria of the clonal Borrelia burgdorferi strain N40 as described (39).  
Ankle measurements were obtained using a metric caliper before and at 4 weeks of 
infection.  Joint tissue was prepared for assessment of histopathology as described (21).  
Ankle measurements and histopathology were assessed in a blinded fashion.  Infection 
was confirmed in mice sacrificed prior to 14 days of infection by culturing bladder tissue 
in BSK II media containing 6% rabbit serum, phosphamycin, and rifampicin.  ELISA 
quantification of B. burgdorferi-specific IgM and IgG concentrations were used to 
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confirm infection in mice euthanized at and after 14 days of infection as described (11, 
34). 
 
Preparation of single cell suspensions from mouse tissue  
Single cell suspensions were prepared from rear ankle joint tissue as described 
previously (21), with a few modifications.  After excision, joints were placed into Petri 
dishes containing 3 ml digestion buffer.  For flow cytometry experiments, the buffer 
consisted of 1mg/ml collagenase A (Roche), 10mM NaN3, and 5% NCS in HBSS.  For 
experiments where joint cells were sorted for transcriptional analysis, the buffer consisted 
of endotoxin-free Liberase TM (Roche) at 0.2 mg/ml in RPMI 1640. Collagenase 
digestions were incubated for 2 hours at 37° C, while Liberase digestions were incubated 
for 1 hour at 37° C.  After incubation, digestion reactions were filtered through a 100 µm 
cell strainer, centrifuged, and the red blood cells lysed.  Single cell suspensions of lymph 
nodes were prepared by smashing lymph nodes through a 100µm cell strainer into Petri 
dishes containing flow cytometry buffer.  Blood was obtained by cheek puncture, and 
collected in eppendorf tubes containing acid citrate dextrose (ACD).  Blood leukocytes 
were isolated as described (40). 
 
Flow cytometry 
All flow cytometry data were analyzed using BD CellQuest Pro software.  Sorting 
experiments were performed using a BD FACSAria II.  All other FACS data were 
collected on a BD FACS Canto II flow cytometer.  7’AAD (eBioscience) was used in all 
experiments (excluding samples stained for FoxP3), and dead cells were excluded from 
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analyses, as were doublet cells.  At least 105 viable, nondoublet events were acquired for 
each sample.  All antibodies used for flow cytometry were purchased from either 
BioLegend or eBioscience.  Unconjugated Fc blocking antibody (clone 93 eBioscience) 
was included in all antibody-labeling experiments.  Fluorochrome-conjugated antibodies 
used in this study were as follows: FITC conjugated α-CD4 (RM4-4), α-CD8α (53-6.7), 
α-B220 (RA3-6B2), α-F4/80 (BM8), α-TCR-β (H57-597); PE conjugated α-CD3ε (145-
2C11), α-NK1.1 (PK136), α-NKp46 (29A1.4), α-Ly6C (HK1.4), α-F4/80 (BM8), α-
FoxP3 (FJK-16s); PE-Cy-7 conjugated α-CD4 (GK1.5), α-CD11b (M1/70), α-TCR-β 
(H57-597); APC conjugated α-CD3ε (145-2c11), α-CD11c (N418), αCD45.1/Ly5.1 
(A20), α-F4/80 (BM8), α-TCR-β (H57-597); Alexa Fluor 700 conjugated α-CD8α (53-
6.7), α-Ly6G/Ly6C (RB6-8C5); Pacific Blue conjugated α-CD45.2 (104), α-B220 (RA3-
6B2), α-TCR-β (H57-597).  
 
Injection of monoclonal antibodies 
Antibodies used in neutralization or depletion studies were purchased from Bio X 
Cell, and were aggregate and endotoxin free, and sterile.  Antibodies used were as 
follows: α-IFN-γ (XMG1.2), α-CD4 (GK1.5), and α-NK1.1 (PK-136).  Isotype control 
antibodies used were: Rat IgG1 (HPRN), Rat IgG2b (LTF-2) termed isotype 2, and 
Mouse IgG2a (C1.18) termed isotype 1.  All antibodies were delivered by intra peritoneal 
injection.  For neutralization of IFN-γ, mice were initially injected with 1mg α-IFN-γ or 
isotype control antibody one day prior to infection.  Additional doses of 0.5mg α-IFN-γ 
or isotype control were administered every 4-5 days.  For depletion of CD4+ T cells, mice 
were injected with 200µg α-CD4, or isotype control antibody, one day prior to, and the 
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day of infection.  Depletion was maintained with additional 200µg injections every 5 
days.  Depletion efficiency was determined to be >95% at time of sacrifice in both the 
spleen and blood.  For depletion of NK cells, mice were injected with 250µg α-NK1.1, or 
isotype control antibody one day prior to, and the day of infection.  Depletion efficiency 
was 80-90% in the spleen and blood.  
 
Isolation of RNA and quantitative RT-PCR 
For all experiments examining gene expression in joint tissue, mice were killed, 
and the skin was removed from the tibiotarsal joints.  Ankle joints were excised, placed 
in eppendorf tubes, and frozen immediately in dry ice/ethanol, and stored at -80°C.  
Isolation of total RNA from joint tissue was performed by acid guanidine extraction as 
described (41).  5µg joint RNA was reverse-transcribed as described (21). Primers 
sequences used in this study were: CXCL-10 Forward (5’-GAA ATC ATC CCT GCG 
AGC CTA TCC-3’), Reverse (5’-GCA ATT AGG ACT AGC CAT CCA CTG GG-3’, 
F4/80 Forward (5’-TGG GAA AGA CTG GAT TCT GGG-3’), Reverse (5’-GGA GCC 
ATT CAA GAC AAA GCC-3’); CD4 Forward (5’-CAA GAA GCA GAG TGA AGG 
AAG GAC-3’), Reverse (5’-CAG CAG CAG CAG CAA GCG-3’); CD49b Forward (5'-
ATA AGG AGT GTG GCA GCG ATG G-3'), Reverse (5'-CCC CTC TGT TTT TCA 
GGA TGA CTG-3'); IL-10CD (does not recognize sterile transcript produced by IL-10-/- 
mouse) Forward (5’-GCT CTT ACT GAC TGG CAT GA-3’), Reverse (5’-TTC CGA 
TAA GGC TTG GCA AC-3’.  Primer sequences for β–actin (39), CXCL-9 (21), IGTP 
(39), IIGP (39), and Vα14-Jα18 iTCR (42) used in this study can be found with their 
respective citations.  All RT-PCR experiments were conducted on a Roche LC-480. 
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Isolation of DNA and quantification of joint spirochetes 
For quantification of joint spirochetes at 4 weeks post infection, total DNA was 
isolated as described (12).  Quantitative PCR was performed on a Roche LC-480.  
Spirochete quantification was performed by amplification of the B. burgdorferi recA 
gene, followed by normalization to the mouse nidogen gene.  
 
Generation of radiation chimeras 
IL-10-/- mice 5 weeks of age were lethally irradiated with 2 doses of 525 cGy 3 
hours apart using a GE Isovolt Titan.  Twenty-four hours post irradiation; splenocytes 
were harvested from donor mice (either IL-10-/- Ly5.2+, or WT congenic B6 mice that 
were Ly5.1+).  Irradiated mice were then injected i.v. with 2×107 splenocytes in a 200µl 
volume.  Chimerism was determined at 2, 4, 6, and 14 weeks after irradiation by flow 
cytometry analysis of blood leukocytes.  After full reconstitution, B cells and myeloid 
lineage cells were found to be >90% donor-derived, while T cells were approximately 
60% donor-derived.  For a summary of reconstitution efficiency see (Appendix A). 
 
ELISA analysis of serum IFN-γ 
Blood was obtained from mice by submandibular puncture at the time of 
euthanasia.  Blood was allowed to clot, centrifuged, and serum was collected, and stored 
at -20°C prior to analysis.  IFN-γ concentration in serum samples were detected by 
sandwich ELISA using clone R46A2 as the capture antibody, and biotinylated antibody 
(XMG1.2) for detection. 
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Data and statistical analyses 
All graphical data represent the mean ± SEM.  Statistical analysis was performed 
using Prism 5.0c software.  Unless otherwise indicated, data were analyzed by one-way 
ANOVA with the Bonferoni post-hoc test for pair-wise comparisons.  Categorical data 
for histopathology was assessed by the Mann Whitney U test.  Statistical significance is 
indicated by (*), (**), or (***) with p values of < 0.05, < 0.01, and < 0.001 respectively. 
 
Results 
Localized production of arthritis-modulating IL-10 in joint tissue is 
dependent on infiltrating leukocytes 
Previous publications with IL-10-/- mice have established a unique role for IL-10 
in modulating the inflammatory response to B. burgdorferi, restricting the severity of 
arthritis while permitting bacterial survival within joint tissue (36, 43).  Microarray 
analyses of infected joint tissue further revealed a sustained induction of transcripts for 
IFN-γ and interferon-inducible genes in B6 IL-10-/- mice, but not WT B6 mice, beginning 
2 weeks following infection (39).  These findings suggested that suppression of arthritis 
in B6 mice was dependent on a tissue-localized source of IL-10, possibly acting to 
suppress local production of IFNγ.  As arthritis in B6 mice is more severe in the absence 
of IL-10, we sought to determine the cellular source(s) of this anti-inflammatory 
cytokine.  For the initial characterization, IL-10-/- mice were lethally irradiated, and 
served as recipients for Ly5.1+ WT B6 splenocytes, or autologous Ly5.2+ IL-10-/- 
splenocytes in a protocol designed for complete reconstitution of both hematopoietic 
lineage cells and hematopoietic stem cells.  Mice were infected 12 weeks after 
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irradiation/transplantation and sacrificed 2 weeks later, whereupon IL-10, IFN-γ, and 
interferon-inducible gene expression were assessed by RT-PCR.  Importantly, expression 
of IL-10 in the joint tissue of Ly5.1→IL-10-/- chimeric mice was equivalent to IL-10 
expression in joint tissue of un-irradiated, infected, WT B6 mice (Figure 2.1A), whereas 
IL-10 transcripts were not detectable in IL-10-/- mice reconstituted with splenocytes from 
IL-10-/- mice.   Evidence that active IL-10 protein was produced in the joint tissue of 
Ly5.1→IL-10-/- chimeras is provided by the resulting suppressed expression of IFN-γ and 
the interferon responsive transcripts CXCL-9 and CXCL-10 to levels found in the joint 
tissue of infected wild type B6 mice (Figure 2.1B, C, D).  Thus, leukocyte derived IL-10 
is sufficient to suppress the interferon-inducible response in the joint tissue of Borrelia 
burgdorferi infected B6 mice. 
 
Both CD4+ T cells and macrophages are sources of IL-10 in the 
B. burgdorferi-infected joint 
To identify the IL-10-producing cell type(s) infiltrating joint tissues during B. 
burgdorferi infection, an IL-10 reporter mouse in which an IRES-GFP cassette was 
knocked into the 3’ UTR of the IL-10 gene was utilized.  The availability of this mouse, 
designated “tiger”, on the B6 background allowed direct assessment of the cell types 
responsible for IL-10 production in response to B. burgdorferi by flow cytometry of cells 
recovered from localized tissue (44).  Joint tissue and inguinal lymph nodes were 
collected from uninfected control mice or from mice at day 14 of infection, the time 
previously associated with up-regulated levels of IL-10 in WT B6 mice (39).  Single cell 
suspensions were prepared from inguinal lymph nodes and from joint tissue disrupted by 








Figure 2.1. A hematopoietic source of IL-10 regulates expression of interferon-
inducible transcripts.  RT-PCR analysis of joint tissue at 2 weeks after infection with B. 
burgdorferi from WT B6 (N=8), B6 IL-10-/- (N=8), WT LY5.1→IL-10-/- chimeras 
(N=8), and IL-10-/-→IL-10-/- chimeras (N=6).  Expression of IL-10 (A), IFN-γ (B), 
CXCL-9 (C), and CXCL-10 (D), was normalized to β-actin.  The term ‘ND’ indicates that 
IL-10 transcripts were not detected (A).  Statistical analysis was performed as described 
in Materials and Methods. 
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enzymatic digestion, as described in Materials and Methods, and stained with lineage 
markers.  Lymph node and joint cells from uninfected tiger mice or control mice showed 
little to no GFP+ cells in either the CD45+ or CD45- fraction (Figure 2.2A, i-ii, iv-v), 
consistent with the observation that IL-10 expression is extremely low in uninfected mice 
(Figure 2.1A).  However, initial analysis of both tissues from infected tiger mice revealed 
a small population of IL-10 (GFP)+ cells, all of which also expressed the common 
leukocyte antigen, CD45.2, (Figure 2.2A, iii, vi).  The observation that all IL-10 (GFP)+ 
cells were also CD45.2+, is consistent with data obtained with radiation chimeras, which 
concluded that anti-inflammatory IL-10 is leukocyte-derived (Figure 2.1A).  Further 
characterization of the IL-10 (GFP)+ cells in the draining lymph nodes of infected tiger 
mice revealed them to also stain as TCR-β+ and CD4+ (Figure 2.2B, iii, iv) with very few 
GFP+ cells staining positive for NK1.1, CD8α, or B220 (Figure 2.2B, ii, v, vi).  When 
total IL-10 (GFP)+ lymph node cells were gated, >90% of these cells were double 
positive for CD4 and TCR-β (Figure 2.2C), demonstrating that CD4+ T cells are the 
primary source of IL-10 in the inguinal lymph nodes of B. burgdorferi infected mice. 
 To identify the specific lineages of the CD45+, IL-10 expressing cells in the joint 
tissue at 2 weeks of infection, single cell suspensions were prepared from infected joint 
tissue, and stained with the same lineage markers used to analyze lymph node cells.  As 
previously indicated, 1.39% of joint cells were IL-10 (GFP)+ (Figure 2.1A, vi).  Further 
analysis of joint cell lineages identified populations of GFP+ cells that also stained 
positive for TCR-β and CD4, at a frequency of 0.22% and 0.23% respectively (Figure 
2.2D, iii, iv).  As was seen in the infected lymph nodes, IL-10 (GFP)+ cells had little to no  




Figure 2.2. IL-10 expression in vivo is found in both CD4+ T cells and 
macrophages.  Flow cytometry data in A-E utilized primarily lymphoid markers to 
designate populations, while date from F-G represent a separate myeloid analysis.  Gate 
boundaries for GFP and lineage markers were established by isotype control staining in 
cells derived from non-tiger mice.  Data from A-iii, vi, and B-G were acquired from a 
single infected tiger mouse at 2 weeks after infection.  Analysis of three infected tiger 
mice yielded similar results.  IL-10 (GFP) expression in CD45+ cells from infected tiger 
mice, in both the lymph nodes (A-iii) and joint tissue (A-vi).  IL-10 (GFP) expression in 
the tissues of non-tiger or uninfected tiger mice (Ai, ii, iv, v).  Analysis of lineage-
specific surface markers that were present on IL-10 (GFP)+ cells in infected lymph nodes 
(B).  Frequency of CD4+, TCR-β+ T cells in the total IL-10 (GFP)+ cells in lymph node 
tissue (C).  Analysis of lymphocyte lineage-specific surface markers that were present on 
IL-10 (GFP)+ cells in infected joint tissue (D).  Frequency of CD4+, TCR-β+ T cells in the 
total IL-10 (GFP)+ cells in infected joint tissue (E).  Analysis of myeloid lineage-specific 
surface markers that were present on IL-10 (GFP)+ cells in infected joint tissue (F).  
Frequency of CD11b+, F4/80+ macrophages in the total IL-10 (GFP)+ cells in infected 
joint tissue (G). 
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staining for NK1.1, CD8α, or B220 (Figure 2D, ii, v, vi).  When total IL-10 (GFP)+ joint 
cells were gated, 19% stained double positive for TCR-β and CD4 (Figure 2E), 
demonstrating that CD4+ T cells are significant source of IL-10 in the infected joint.  
Because CD4+ T cells accounted for one fifth of the total IL-10 expressing cells, a second 
non-T cell, non-lymphocyte source of IL-10 in the infected joint was suspected.  
Additional analysis of joint cells from infected tiger mice revealed that IL-10 (GFP+) 
cells stained positive for CD11b and for the macrophage marker F4/80, both at a 
frequency of 1.08% (Figure 2.2F, i, iv), indicating a myeloid source of IL-10.  Very few 
of the GFP+ cells were positive for CD11c or Gr-1/Ly6c (Figure 2.2F, ii, iii), thus neither 
dendritic cells nor granulocytes are major sources of IL-10 in the joint.  When total IL-10 
(GFP)+ cells were gated, 80% stained double positive for CD11b and F4/80, identifying 
these cells as macrophages (Figure 2.2G), and accounting for the non-T cell source of IL-
10 in the infected joint.  Together these data indicate that CD4+ T cells are the primary 
source of IL-10 in the draining lymph nodes of infected B6 mice, while both tissue 
macrophages and CD4+ T cells produce IL-10 in the joint tissue of B. burgdorferi 
infected mice. 
 
Kinetic analysis of IL-10 expression in joint tissue  
The duration and magnitude of IL-10 expression in response to B. burgdorferi 
infection in the joint tissue was further assessed in tiger mice by flow cytometry, at 7, 11, 
and 14 days of expression.   CD4+ T cells were quite rare in joint tissue of uninfected 
animals and at day 7  after infection (Figure 2.3A-i, ii, and 3B).   A robust infiltrate of 
CD4+ T cells was observed, that peaked at day 11 of infection, with 45% of the CD4+ T 






Figure 2.3.  Kinetic analysis of IL-10 expressing cells in tiger mice.  Control and 
infected tiger mice (N=3 per group) were analyzed for IL-10 (GFP) producing CD4+ T 
cells and macrophages in joint tissue.  Flow cytometry analysis of IL-10 expression in 
joint CD4+ TCR-β+ T cells from uninfected mice (A-i), or mice at day 7 after infection 
(A-ii), day 11 after infection (A-iii), and day 14 post infection (A-iv).  Total joint CD4+ 
TCR-β+ T cells (B) and total IL-10 (GFP)+ CD4+ TCR-β+ T cells (C).  Frequency of CD4+ 
TCR-β+ FoxP3+ Treg cells in lymph nodes and joint tissue at day 11 after infection (D).  
Comparison of total joint IL-10 (GFP)+ CD4+ TCR-β+ T cells and total joint CD4+ TCR-
β+ FoxP3+ Treg cells in joint tissue at day 11 after infection (E).  Total CD11b+, F4/80+ 
macrophages (F), and IL-10 (GFP)+ CD11b+, F4/80+ macrophages (G) in joint tissue.  
Statistical analyses were performed as reported in Materials and Methods.  Statistical 
significance in (E) was determined using student’s T test.  
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cells expressing IL-10 (GFP), (Figure 2.3A iii) and 3B).   By day 14 after infection the 
percentage and total number of infiltrating CD4+ T cells expressing IL-10 (GFP) had 
dropped to 21% (Figure 2.3A, iv, 3C).  To determine whether regulatory T cells (Treg) 
were responsible for this IL-10 response, joint cells from day 11 tiger mice were also 
analyzed for the Treg definitive transcription factor, FoxP3.  Because, concurrent analysis 
of IL-10 (GFP) and FoxP3 was not possible due to loss of cytoplasmic GFP from cells 
treated to allow intranuclear FoxP3 staining, the distributions of GFP+ and FoxP3+ T cells 
were assessed.  In the day 11 lymph nodes, 12% of the CD4+ T cells were FoxP3+, 
consistent with other reports that Treg cells account for ~10% of CD4+ T cell population.  
Only 1-2% of the CD4+ T cells in lymph nodes were IL-10 (GFP)+ (data not shown).  In 
joint tissue at day 11 after infection, only 12% of the CD4+ T cells displayed intracellular 
staining for FoxP3 (Figure 2.3D-ii), while 45% of the total infiltrating CD4+T cells 
expressed IL-10 (GFP) (Figure 2.3A iii).  Thus, the number of IL-10 (GFP)+ CD4+ T cells 
was significantly greater than the number of FoxP3+ CD4 T cells in the joint tissue 
(Figure 2.3E).  This observation suggests that the IL-10 producing CD4+ T cells in the 
joint consist of both Treg and non-Treg cells.  As in previous experiments, CD11b+ F4/80+ 
macrophages constituted a major portion of cells recovered from the joint tissue after 
collagenase digestion.  The maximal infiltration of total and IL-10 (GFP) expressing 
macrophages into the joint tissue was at day 11 of infection, and levels remained elevated 
at day 14 (Figure 2.3F-G).  Although both the GFP mean fluorescence intensity (MFI) 
and frequency of IL-10 (GFP) expression in the total CD4+ T cell population was 
significantly greater than in the macrophage population at 11 and 14 days of infection 
(Table 2.1), IL-10 (GFP+) macrophages in the joint were more plentiful than CD4+ T cells 








Cell Type Day of Infection
GFP+ (% of 
population)a
Total GFP+ 
Cells (x 1,000) GFP MFI b
CD4+ T cells 11 44.0+3.1** c 20.2+1.6 57.3+4.9*
Macrophages 11 6.21+1.1 25.7+6.1 23.9+0.4
CD4+ T cells 14 24.6+4.0* 4.0+1.0 37.2+2.5*
Macrophages 14 4.66+1.2 15.2+3.8* 20.95+0.5
Table 2.1  Comparison of IL-10 (GFP) contributions between 
macrophages and CD4+ T cells in the joint tissue of B. burgdorferi 
infected 'tiger'  mice.
aValues represent the mean + S.E.M
bMean Fluorescence Intensity
cStatistical significance (*) or (**) indicate p values of <0.05 and <0.01 
respecively, by student's t-test.
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at day 14 after infection (Table I).  Thus, on a single cell basis, CD4+ T cells produce 
more IL-10 than their macrophage counterparts, but as distinct populations, macrophages 
and CD4+ T cells are comparable in their ability to produce IL-10.  
 
Both systemic and localized production of IFN-γ is associated with 
increased arthritis severity in IL-10-/- mice 
Previous microarray analysis revealed a sustained up-regulation of IFN-γ and 
interferon-inducible genes in the joint tissue of infected IL-10-/- mice at 2 and 4 weeks 
after infection (39).  Further analysis of serum samples from infected mice revealed a 
dramatic increase of IFN-γ in infected IL-10-/- mice, relative to modest induction in WT 
B6 mice, confirming a systemic dysregulated inflammatory response in B. burgdorferi 
infected IL-10-/- mice (Figure 2.4A).  Localized and systemic production of IFN-γ was 
thus hypothesized to be responsible for the increased arthritis severity in IL-10-/- mice 
infected with B. burgdorferi. To directly assess involvement of IFN-γ, B. burgdorferi 
infected B6 IL-10-/- mice were treated with an IFN-γ-neutralizing antibody, an isotype 
control antibody, or PBS alone, at 5-day intervals throughout the four-week B. 
burgdorferi infection.  Arthritis severity at 4 weeks after infection in B6 IL-10-/- mice 
receiving PBS or control antibody injections was similar, and more severe than WT B6 
control mice (Figure 2.4B).  However, neutralization of IFN-γ in infected IL-10-/- mice 
significantly reduced ankle swelling (Figure 2.4B) and histopathology scores (Table II).  
Interestingly, treatment of infected B6 IL-10-/- mice with the IFN-γ-neutralizing antibody 
had a modest effect on spirochete numbers in joint tissue relative to control IL-10-/- mice  









Figure 2.4.  IFN-γ is responsible for the increased arthritis severity in B6 IL-10-/- 
mice.  ELISA of serum IFN-γ at 2 weeks of infection in B6 and IL-10-/- mice (N=5 mice 
per group (A).  Arthritis was assessed in WT B6 and IL-10-/- mice at 4 weeks of infection 
(N≥8 mice per group).  B6 IL-10-/- mice were injected with PBS, control antibody, or α-
IFN-γ over the course of infection.  Ankle swelling was used to assess arthritis severity 
(B).  Quantification of joint spirochetes at 4 weeks of infection, using qPCR (C).  
Statistical analyses were performed as reported in Materials and Methods. 
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(Figure 2.4C).  Thus, the enhanced control of bacterial number in IL-10-/- mice appears to 
be partially dependent on IFN-γ.   We hypothesize that the other functions of IL-10, 
independent of suppressive effects on IFN-γ, may assist in host defense, as demonstrated 
by significant effect on mononuclear cell infiltration (addressed in the following sections 
and Table 2.2).  Taken together, these data suggest that IL-10 acts to suppress both 
arthritis and host defense via its regulatory effects on IFN-γ. 
 
IFN-γ is required for early induction of interferon-responsive transcripts and 
for chemokines known to perpetuate recruitment of inflammatory cells 
The ability of IFN-γ neutralization to suppress the severity of Lyme arthritis in IL-
10-/- mice, (Figure 2.4B, Table II), suggested it functioned locally through the induction 
of inflammatory response and chemokine production in the joint tissue.  To characterize 
the involvement of IFN-γ early in the development of arthritis, prior to the end stage of 
disease, we assessed the presence of interferon-inducible transcripts at 2 weeks of 
infection in B6 IL-10-/- mice treated with PBS, isotype control antibody, or IFN-γ-
neutralizing antibody.  Consistent with previous results, interferon-inducible transcripts, 
including those for the chemokines cxcl9 and cxcl10, were expressed at low levels in 
infected WT B6 mice and were highly upregulated in the joint tissue of infected B6 IL-
10-/- mice injected with either PBS or control antibody (Figure 2.5A-D).  In contrast, IL-
10-/- mice treated with IFN-γ-neutralizing antibody displayed a dramatic reduction in 
expression of these transcripts, similar to that seen in WT B6 mice (Figure 2.5A-D).  
These results, coupled with those of Figure 2.4B and Table II, implicate IFN-γ in both the 
up regulation of pro-inflammatory transcripts in the joint tissue beginning at 2 weeks of 
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B6 IL-10-/- PBS (none) 2.88+1.0 2.38+0.46 1.00+0.19 2.38+0.32
B6 IL-10-/- Isotype 2.55+0.77 1.91+0.34 1.27+0.30 2.27+0.24
B6 IL-10-/- !-IFN-" 1.50+0.43** 1.17+0.27 0.33+0.19** 1.08+0.23**
aAssessed at 4 weeks of infection, as described in Materials and Methods
bValues represent mean + S.E.M.
Statistical significance between !-IFN-" and Isotype is indicated by (**).  p<0.01 by 
Mann Whitney U test









Figure 2.5. IFN-γ is responsible for the robust expression of interferon-inducible 
transcripts in B6 IL-10-/- mice.  RT-PCR analysis of interferon-inducible transcripts in 
joint tissue at 14 days of infection in WT B6 and B6 IL-10-/- mice injected with PBS, 
isotype control antibody, or α-IFN-γ.  N≥6 per group.  Expression was normalized to β-
actin and values represent means ± SEM.  Expression of interferon-inducible CXCL-9 
(A), CXCL-10 (B) Iigp (C) and Igtp (D) transcripts are shown.  Statistical analyses were 
performed as reported in Materials and Methods. 
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infection and in the increased severity of arthritis seen at 4 weeks of B. burgdorferi  
infection of B6 IL-10-/- mice. 
 
Immune cell infiltration is regulated by IL-10 in infected B6 mice, and is 
partially dependent on IFN-γ 
Histopathology of joint tissue from infected IL-10-/- mice highlighted an IFN-γ-
dependent increase in the mononuclear cell infiltrate (Table II).  We reasoned that 
perhaps an early cellular infiltrate into the B. burgdorferi-infected joint tissue of IL-10-/- 
mice should contain potential cellular sources of IFN-γ as well as interferon responsive 
transcripts.  To characterize this cellular infiltrate into the infected joint, single cell 
suspensions were prepared from joint tissue from WT B6 and IL-10-/- mice at 2 weeks 
after infection.  Increased frequencies of T cells, NK cells, NKT cells, and macrophages 
were observed into the joint tissue of both WT B6 and B6 IL-10-/- mice, relative to 
uninfected controls (Figure 2.6A-B) at 2 weeks of infection.  Levels of T cells, NK T 
cells, and macrophages were 2-3 fold greater in joint tissue of infected IL-10-/- mice than 
in WT B6 mice (Figure 2.6A, iv and 6B, iv).  Many of these cell types have been reported 
to produce IFN-γ during B. burgdorferi infection, as well as in other infection models.  
Because neutralization of IFN-γ in IL-10-/- mice resulted in a decreased mononuclear 
infiltrate into the joint tissue of IL-10-/- mice (Table II), and this cytokine was also 
required for the expression of chemokines (CXCL-9 and CXCL-10) known to play a role 
in the recruitment of NK cells, T cells, and macrophages, it was hypothesized that IFN-γ 
would be required for the infiltration of one or more of these cells types.  To test this 
hypothesis, B6 IL-10-/- mice were treated with the IFN-γ-neutralizing antibody during a 2-  







Figure 2.6.  Ankle infiltration by multiple immune cells is regulated by IL-10 in 
infected B6 mice, and is partially dependent on IFN-γ.  Flow cytometry analysis of joint 
single cell suspensions in WT B6 and B6 IL-10-/- mice.  Data in A and B were acquired 
from six pooled joints from 3 B6 and 3 IL-10-/- mice.  Frequency of NK cells, NKT cells, 
α/β T cells in uninfected WT B6 (A-i), uninfected B6 IL-10-/- (A-ii), 2 week infected WT 
B6 (A-iii) and 2 week infected B6 IL-10-/- (A-iv) ankle joints.  Frequency of macrophages 
in uninfected WT B6 (B-i), uninfected B6 IL-10-/- (B-ii), 2 week infected WT B6 (B-iii), 
2 week infected B6 IL-10-/-  (B-iv) ankle joints.  Infiltration of NK cells (C), NKT cells 
(D), α/β T cells (E) and macrophages (F) in joint tissue at 14 days of infection in WT B6 
and B6 IL-10-/- mice injected with PBS, isotype control antibody, or α-IFN-γ.  N≥3 for 
each group.  Statistical analysis was performed as described in Materials and Methods.   
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week B. burgdorferi infection.  Low levels of infiltrating T cells, NK cells, NKT cells,  
and macrophages were observed in the infected joint tissue of WT B6 mice at 2 weeks of 
infection, but high levels of these cells were observed in the infected joint tissue of B6 
IL-10-/- mice at the same interval (Figure 2.6C-F).  In contrast, B6 IL-10-/- mice treated 
with the IFN-γ-neutralizing antibody had significantly fewer numbers of infiltrating NK 
and NKT cells (Figure 2.6C-D), indicating strong dependence on localized effects of 
IFN-γ.  The finding that the number of infiltrating macrophages and T cells in the joint 
were not reduced by IFN-γ neutralization suggests that recruitment of these cells is not 
solely dependent on IFN-γ (Figure 2.6E-F), but that their infiltration is regulated by IL-
10.  This may explain the modest effect of IFN-γ neutralization on enhanced bacterial 
control in the joint tissue of IL-10-/- mice, which was less dependent on IFN-γ than was 
arthritis development (Figure 2.4B). 
 
Multiple cell types recruited to the infected joint tissue of  
IL-10-/- mice produce IFN-γ 
Canonical sources of IFN-γ include TH1 polarized CD4 T cells, NK cells and 
NKT cells, all of which are found in the joint tissue of B. burgdorferi infected IL-10-/- 
mice and have been previously associated with IFN-γ production during B. burgdorferi 
infection (17, 21, 42, 45-47).  Although B cells from the infected lymph node have also 
been linked to IFN-γ production (48), B220+ cells were not detected in the infected joint 
tissue of WT B6 or B6 IL-10-/- mice (Figure 2.2D iv, and data not shown).  To identify 
the cell types responsible for IFN-γ production, as well as interferon-inducible gene 
expression in the joint tissue, IL-10-/- mice were injected with GK1.5, a CD4 T cell-
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depleting antibody, or PK136, an NK/NKT cell-depleting antibody, followed by periodic 
booster injections of depleting antibody during the course of infection with B. 
burgdorferi.  Only depletion of CD4+ T cells reduced the presence of IFN-γ in the serum 
of infected IL-10-/- mice, suggesting these cells are the most important source driving 
systemic production of IFN-γ (Figure 2.7A).  Depletion of CD4+ T cells, but not NK 
cells, resulted in a significant reduction in CXCL-9 transcripts, but only a modest 
reduction of CXCL-10 transcripts in the joint tissue at 2 weeks of infection in IL-10-/- 
mice, (Fig 7B-C).  This suggests either that depletion of suspected cell types was 
insufficient in the joint, or that multiple cell types produce IFN-γ in response to B. 
burgdorferi spirochetes in the joint.  
To identify the joint infiltrating cells responsible for the production of IFN-γ, 
single cell suspensions of joint tissue were prepared from B6 IL-10-/- mice 2 weeks after 
infection, labeled for lineage markers, and FACS was utilized to sort specific 
populations.  Total RNA was then extracted from the sorted cells, and IFN-γ, and lineage 
specific markers were quantified by RT-PCR in each fraction.  Cell lineages were defined 
in the following manner: NK cells as NK1.1+ TCR-β-; NKT cells as NK1.1+, TCR-β+; 
CD4+ T cells as NK1.1-, TCR-β+, and CD4+, and Macrophages F4/80+.  IFN-γ transcripts 
were highly enriched in sorted fractions containing NK cells and CD4+ T cells recovered 
from the infected joint tissue of IL-10-/- mice, but no enrichment of IFN-γ was observed 
in sorted NKT cells, macrophages, unfractionated joint cells (Figure 2.8A), or whole joint 
(Figure 2.1B).  Thus, as was previously postulated (Figure 2.7), two cell types, NK cells 
and CD+ T cells, but not NKT cells, are responsible for localized production of IFN-γ in 
B. burgdorferi infected IL-10-/- mice.   









Figure 2.7.  Depletion of CD4+ T cells but not NK/ NKT cells reduces expression 
of interferon inducible transcripts.  Analysis of serum IFN-γ and interferon-inducible 
transcripts in joint tissue at 14 days of infection (N≥7).  B6 IL-10-/- mice were injected 
with PBS, Mouse IgG2a (Isotype 1), α-NK1.1, Rat IgG2b (Isotype 2), or αCD4 during 
infection.  ELISA analysis of serum IFN-γ (A).  Expression of CXCL-9 (B) and CXCL-10 
(C) in joint tissue was assessed by RT-PCR. Expression was normalized to β-actin.  
Statistical analysis was performed as described in Materials and Methods.   
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Figure 2.8.  Joint CD4+ T cells and NK cells express high levels of IFN-γ during 
B. burgdorferi infection.  RT-PCR analysis of sorted lineages from infected B6 IL-10-/- 
joint tissue (N=4).  NK cells (NK1.1+ TCR-β-, NKT cells (NK1.1+ TCR-β+), CD4+ T cells 
(NK1.1- TCR-β+ CD4+ CD8-) and macrophages (F4/80+) were sorted simultaneously.  
Expression of IFN-γ transcripts (A) and the transcripts of the definitive lineage markers 
CD49b (B), Vα14 iTCR (C), CD4 (D), and F4/80 (E) by RT-PCR was used to confirm 
pure sorted populations. Expression was normalized to β-actin.  Statistical analysis was 
performed as described in Materials and Methods.   
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To confirm that the failure to detect IFN-γ transcripts in the NKT cell or other  
fractions did not reflect a poor recovery of cells, lineage specific transcripts from each of 
the fractions were assessed by RT-PCR.  CD49b (α2 integrin expressed by NK and NKT 
cells) transcripts were enriched in both the NK cell and NKT cell fractions (Figure 2.8B) 
as expected, while expression of the NKT cell specific, Vα14-Jα18 iTCR, was found to 
be enriched only in the sorted NKT cell fraction (Figure 2.8C).  CD4 transcripts were 
enriched in the CD4 T cell fraction (Figure 2.8D).   
 
Discussion 
The IL-10-/- mouse has proven to be a useful tool in the study of the inflammatory 
response to B. burgdorferi on both the arthritis resistant B6 and arthritis susceptible C3H 
backgrounds (36, 43).  An important feature of this model is that the heightened 
inflammatory response permitted in the absence of IL-10 results in 5-to 10-fold fewer 
spirochetes in the joint tissue (36, 43), unlike many other immunodeficiencies, which 
result in higher levels of tissue spirochetes. Thus, a unique feature of this model is the 
observation that very low levels of antigen are capable of triggering an exuberant 
inflammatory response.  Increased arthritis severity in these mice is hypothesized to be 
due to the collateral damage caused by a poorly regulated immune response.  In the 
human Lyme disease patient population there are rare individuals who continue to display 
symptoms of infection even following a regimen of therapy expected to eradicate the 
spirochetes (5, 9).  In some reports, these individuals are treated with anti-inflammatory 
drugs used for rheumatoid arthritis (49), after which, most symptoms resolve.  Hence, we 
hypothesize that the IL-10-/- mouse may provide insight into the involvement of 
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dysregulated response to the initial triggering effect of tissue infiltrating B. burgdorferi, 
and that this may result in delayed resolution of pathological development.   
Previous gene expression analysis of joint tissue from B. burgdorferi -infected 
mice revealed an interferon-inducible response that correlated to increased arthritis 
severity in C3H and B6 IL-10-/- mice (39).  While this response was early (1 week of 
infection), and evanescent in C3H mice, it was delayed (2 weeks) and sustained (4 
weeks) in B6 IL-10-/- mice.  Importantly, only the IL-10-/- mouse displayed induced 
expression of any interferon gene, with IFN-γ transcripts increased by 16- and 22-fold at 
2 and 4 weeks of infection, respectively (39).  A final critical difference between C3H 
and IL-10-/- mice was that the most robustly upregulated transcripts in C3H mice were for 
a group of GTPases, whereas in IL-10-/- mice, the chemokines CXCL-9 and CXCL-10 
were most prominent.  In the present study, systemic production of IFN-γ was also 
observed in IL-10-/- mice (Figure 2.4A), which suggested arthritis developed in these 
mice could be due to failed regulation of IFN-γ expression in the infected joint tissue.  
Indeed, neutralization of IFN-γ reduced arthritis severity (Figure 2.4A, Table 1), 
suppressed the expression of the interferon-inducible transcripts CXCL-9 and CXCL-10 
(Figure 2.5A, B), and limited the early infiltration of NK and NKT cells into the infected 
joints of IL-10-/- mice (Figure 2.6C, D; Figure 2.9).  Joint histopathology also 
demonstrated a reduced mononuclear infiltrate in IL-10-/- mice treated with anti-IFN-γ.  
The observation that infected IL-10-/- mice harbor more macrophages in their joint tissue 
than WT mice (Figure 2.6B, F) provides a possible explanation for the enhanced host 
defense observed in IL-10-/- mice, and supports the conclusion made by Lazarus et al., 
that innate immunity is responsible for the enhanced host defense seen in IL-10-/- mice  







Figure 2.9.  Model of Lyme arthritis development in B6 IL-10-/- mice.  B. 
burgdorferi spirochetes are detected by macrophages and other resident cell types in the 
joint (A).  B. burgdorferi stimulated production of CXCL-9, CXCL-10, and other 
chemokines is exaggerated in IL-10-/- mice (B).  NK cells, NKT cells, CD4+ T cells, and 
other cell types are recruited to the infected joint through the influence of multiple 
chemokines (C).  NK cells and CD4+ T cells produce IFN-γ (D).  Macrophages and other 
cell types in the joint are activated by IFN-γ, and produce a second wave of chemokines, 
including CXCL-9 and CXCL-10, completing a feedback loop (E).  Macrophages and 
CD4+ T cells produce IL-10 (F).  IL-10 regulates the expression of IFN-γ, and subsequent 
production of CXCL-9 and CXCL-10 (G). 
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(50).  This enhanced host defense phenotype was partially abrogated in mice receiving 
anti-IFN-γ (Figure 2.4C).  While the upstream events that culminate in sustained 
production of IFN-γ were not identified, mediation by IL-12 is a possibility as B. 
burgdorferi stimulated IL-10-/- macrophages produced 5 to 10 fold more of this cytokine 
than WT B6 macrophages (unpublished observation). 
These findings highlight a critical difference in arthritis development between 
C3H and B6 IL-10-/- mice.  Whereas arthritis development in C3H mice is dependant on  
Type I interferon and occurs in the absence of IFN-γ (16, 21), our results demonstrate that 
IFN-γ is required for arthritis development in B6 IL-10-/- mice.  Thus we conclude that  
both Type I and Type II interferon pathways can influence arthritis development, 
given the correct circumstances.  Although many of the downstream effectors are 
identical between Type I and Type II interferon signaling, the mechanisms for arthritis 
development between C3H and B6 IL-10-/- mice appears to be distinct.  Of interest was 
the previous finding that the addition of exogenous IL-10 via adenoviral delivery failed to 
suppress arthritis development in C3H mice (43).  This may reflect failure of IL-10 to 
regulate the Type I IFN pathway inherent in the C3H mouse, and further suggests that 
Type I IFN masks pro-arthritic contributions of IFNγ in infected C3H mice (16, 21, 39).   
This supports the observation that Lyme arthritis can occur via multiple mechanisms as 
assessed by genetic linkage analysis, where several pathways have been implicated in 
Lyme arthritis development (51, 52).   
B. burgdorferi induction of IFN-γ has been observed both in vitro and in vivo for 
multiple mouse strains and cell types, as well as in human PBMC’s (53-55).  In C3H 
mice, depletion of NK and NKT cells resulted in reduced expression of most interferon-
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inducible genes, in a near identical fashion to IFN-γ neutralization in C3H mice (21).  
Other studies have linked NKT cells to IFN-γ in murine Lyme carditis and arthritis (42, 
47).  In carditis, IFN-γ signaling limits pathology and serves to activate local 
macrophages and induce killing of B. burgdorferi spirochetes (42).  Our finding indicate 
that CD4+ T cells, but not NK/NKT cells, are responsible for the high levels of IFN-γ in 
the serum of infected IL-10-/- mice (Figure 2.7A), whereas both CD4+ T cells and NK 
cells are the major sources of IFN-γ in the joint tissue of infected IL-10-/- mice (Figure 
2.8A; Figure 2.9).   
The critical role of IL-10 in suppressing tissue specific induction of interferon-
inducible genes and Lyme arthritis development in B6 mice suggested that early and 
consistent local production of IL-10 would be necessary to suppress arthritis severity. A 
variety of cell types are capable of producing IL-10, including components of both the 
innate and adaptive immune response and other cell types associated with tissue function 
and vasculature (56).  In this study, two approaches were employed to link IL-10 to its 
cellular source in the infected joint.  Both radiation chimeras and the IL-10 reporter 
mouse demonstrated that leukocytes were the sources of IL-10 expression in the infected 
joint.  Furthermore, both CD4+ T cells and F4/80+ macrophages were found to express IL-
10 in infected joint tissue with comparable contributions of the detectable GFP reporter 
(Figure 2.2D-F; Table I; Figure 2.9).  Although the subset of CD4+T cell responsible for 
IL-10 production was not indentified in this study, we suspect involvement of TH2, Treg, 
or ever the newly identified Tr1 subset of CD4+ T cells. The finding that FoxP3+ Treg cells 
in the joint were significantly fewer than the total IL-10-producing CD4+ T cells 
suggested that the CD4+ T cell subset(s) responsible for IL-10 expression consist of many 
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non-Treg cells.  The peak of IL-10 expression in the joint occurs at 11 days post infection, 
and prior to the development of arthritis. This suggests that IL-10 has a dampening effect 
on localized inflammation, and serves to prevent pathological development, rather than 
resolve it.  The early suppressive effects of IL-10 are robust and pleiotropic, as they limit 
expression of interferon-inducible genes, pro-inflammatory cytokines, and cellular 
infiltrates into the joint through regulation of IFN-γ-dependant and IFN-γ-independent 
pathways.  The primary function of IL-10 in arthritis development is to suppress 
expression of IFN-γ, which is required for arthritis development in IL-10-/- mice.   
 The IL-10-/- mouse model provides a much-needed model for studying the role of 
IFN-γ in Lyme arthritis development.  While complete IL-10 deficiency represents an 
extreme example of dysregulated inflammation, a host of factors could influence a 
prolonged inflammatory response.  An important finding of the current study is 
demonstration that CD4+ T cells in the infected joint can produce both pro and anti-
arthritic cytokines, and that loss of the anti-inflammatory signal results in increased 
disease severity.  This observation suggests a dominant effect of anti-inflammatory 
signaling, and that any number of events could combine to disrupt a delicate balance 
between bactericidal and pathologic inflammation.  Interestingly, a loss of function 
polymorphism in the human il10r1 gene has recently been reported (57-60), and is 
associated with risk for extra-pulmonary tuberculosis and rheumatoid arthritis (57, 60).  
While it is unlikely that treatment-refractory Lyme arthritis patients test positive for these 
polymorphisms, the end results among these patients and B6 IL-10-/- mice are similar, in 
the elevated expression of IFN-γ and IFN-γ-inducible chemokines, and possibly represent 
the result of an insufficient regulatory response. 
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Introduction 
 
 Lyme disease describes symptoms that occur following infection with the 
spirochete B. burgdorferi, which is transmitted to humans and animals through the bite of 
infected ticks of the genus Ixodes (1-4).  These bacteria cause lesions in the tissues they 
preferentially colonize, namely the skin, heart, nervous system, and joints (4).  The 
hallmark symptom associated with B. burgdorferi infection is the development of a 
‘bull’s eye’ rash at the site of the tick bite, termed erythema migrans (EM) (5).  This rash 
develops within 1 to 2 weeks following infection in the majority of patients, and is 
thought to arise due to a localized and infiltrating inflammatory response, produced by 
innate and adaptive immune cells, as the spirochetes disseminate outward and downward 
from the site of inoculation and associate with the dermal microvasculature (6-10).  
Induced blister fluid extracted from EM lesions demonstrated the presence of multiple 
pro-inflammatory cytokines in the skin (8).  
 The skin is an important tissue for the life cycle of B. burgdorferi.  Not only is it 
the first tissue to encounter the spirochetes when they are deposited into the dermis by the 
feeding Ixodes tick, but it is also the tissue through which larval ticks acquire the 
infection, rendering them capable of further disease transmission.  It is reasonable to 
assume that a robust inflammatory response that significantly reduces the number of B. 
burgdorferi in the host would make it difficult for these bacteria to be acquired in 
subsequent tick feeding, and ultimately, future bacterial transmission to additional hosts.  
Indeed, a cadre of pro-inflammatory cytokines are produced within the EM lesions of 
patients, including IFN-γ, TNF-α, IL-2, IL-4, and IL-6, and it is thought that this 
response is beneficial to the host (8, 11, 12).  Despite this B. burgdorferi-elicited pro-
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inflammatory response in the initial stages of infection, the spirochetes survive and go on 
to infect and replicate within multiple other tissues (5).   
Interestingly, high levels of the anti-inflammatory cytokine IL-10 were also 
reported within the EM lesions of patients (8).  This cytokine has been reported to limit 
the expression and activity of many pro-inflammatory cytokines, including those listed 
above (13, 14).  Multiple infection models in mice have demonstrated that IL-10 
deficiency results in a reduced pathogen burden, however this is often at the expense of 
host-mediated tissue damage (15).  This is also the case with B. burgdorferi infection of 
IL-10-/- mice, where IL-10 deficiency results in 5-10 fold fewer bacteria in the joint 
tissue, but arthritis severity is increased (16).  Thus, the induction of IL-10 is beneficial to 
B. burgdorferi, and this may be a mechanism utilized by the spirochete to dampen, and 
evade the full brunt of the host immune response.   
Previous microarray analyses of infected joint tissue from arthritis resistant B6 
mice and arthritis susceptible C3H and B6 IL-10-/- mice identified IL-10 transcripts to be 
up-regulated only in B6 mice at 2 weeks of infection (17).  Thus, resistance to arthritis 
development in B6 mice was correlated with induction of IL-10.  Microarray analyses of 
infected joint tissue from B6 mice demonstrated a very modest induction of IL-10 
expression, whereas the suppressive effects on CXCL-9 and CXCL-10 transcripts in the 
joint tissue was robust.  It was therefore hypothesized that tissues outside the joint may 
also contribute to the production of anti-arthritic IL-10.  This chapter explores skin as a 
direct source of IL-10 during B. burgdorferi infection. 
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Materials and Methods 
Mice and infection 
C57BL/6 (B6), B6.129P2-IL-10tm1Cgn/J (IL-10-/-), (B6.129S6-Il10tm1Flv/J (tiger), 
mice were purchased from The Jackson Laboratories.  C3H/HeN mice were purchased 
from Charles River Laboratories.  TLR2-deficient mice were provided by Tularik (San 
Francisco, CA) and generated by Deltagen (Redwood City, CA).  All mice were housed 
in the University of Utah Animal Research Center (Salt Lake City, UT) and strict 
adherence to institutional guidelines were followed.  To avoid colitis development, IL-10-
/- mice were kept on antibiotic water (trimethoprim and sulfamethoxazole) until one day 
prior to infection.  Mice were infected with 2×104 bacteria of the clonal Borrelia 
burgdorferi strain N40 as described. Infection was confirmed in mice sacrificed prior to 
14 days of infection by culturing bladder tissue in BSK II media containing 6% rabbit 
serum, phosphamycin, and rifampicin.  ELISA quantification of B. burgdorferi-specific 
IgM and IgG concentrations were used to confirm infection in mice euthanized at and 
after 14 days of infection as described. 
 
Preparation of single cell suspensions from mouse tissue  
Single cell suspensions were prepared from skin surrounding the rear ankle joint, 
by placing skin into Petri dishes containing 3 ml digestion buffer.  The buffer consisted of 
endotoxin-free Liberase TM (Roche) at 0.2 mg/ml in RPMI 1640. Collagenase digestions 
were incubated for 1 hour at 37° C.  After incubation, digestion reactions were filtered 
through a 100 µm cell strainer, centrifuged, and the red blood cells lysed.  Cells were 
resuspended in 200µl of flow cytometry buffer prior to antibody labeling.  Blood was 
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obtained by cheek puncture, and collected in Eppendorf tubes containing acid citrate 
dextrose (ACD).  Blood leukocytes were isolated as described (18). 
 
Flow cytometry 
All flow cytometry data was analyzed using BD CellQuest Pro software.  FACS 
data were collected on a BD FACS Canto II flow cytometry.  7’AAD (eBioscience) was 
used in all experiments, and dead cells were excluded from analyses, as were doublet 
cells.  All antibodies used for flow cytometry were purchased from either BioLegend or 
eBioscience.  Unconjugated Fc blocking antibody (clone 93 eBioscience) was included in 
all antibody-labeling experiments.  Fluorochrome-conjugated antibodies used in this 
study were as follows: FITC conjugated α-B220 (RA3-6B2); PE conjugated α-CD3ε 
(145-2C11), α-F4/80 (BM8); PE-Cy-7 conjugated α-CD4 (GK1.5), α-CD11b (M1/70); 
APC conjugated α-CD11c (N418), αCD45.1/Ly5.1 (A20), α-TCR-β (H57-597); Pacific 
Blue conjugated α-CD45.2 (104). 
 
Isolation of RNA and quantitative RT-PCR 
For all experiments examining gene expression in skin tissue, mice were killed, 
and the skin was removed from the tibiotarsal joints, or a small section of the back where 
needle inoculation had occurred.  Skin samples were placed in Eppendorf tubes, and 
frozen immediately in dry ice/ethanol, and stored at -80°C.  Isolation of total RNA from 
skin tissue was performed by acid guanidine extraction as described.  Five micrograms of 
skin RNA were reverse-transcribed as described.  Primers sequences used in this study 
were: CXCL-10 Forward (5’-GAA ATC ATC CCT GCG AGC CTA TCC-3’), Reverse 
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(5’-GCA ATT AGG ACT AGC CAT CCA CTG GG-3’; IL-10CD (does not recognize 
sterile transcript produced by IL-10-/- mouse) Forward (5’-GCT CTT ACT GAC TGG 
CAT GA-3’), Reverse (5’-TTC CGA TAA GGC TTG GCA AC-3’.  Primer sequences 
for β–actin (17), CXCL-9 (19), and the B. burgdorferi 16s rRNA (17) used in this study 
can be found with their respective citations.  All RT-PCR experiments were conducted on 
a Roche LC-480. 
 
Generation of radiation chimeras 
IL-10-/- mice 5 weeks of age were lethally irradiated with 2 doses of 525 cGy 3 
hours apart using a GE Isovolt Titan.  Twenty-four hours after irradiation; splenocytes 
were harvested from donor mice (either IL-10-/- Ly5.2+, or WT congenic B6 mice that 
were Ly5.1+).  Irradiated mice were then injected i.v. with 2×107 splenocytes in a 200µl 
volume.  Chimerism was determined at 2, 4, 6, and 14 weeks after irradiation by flow 
cytometry analysis of blood leukocytes.  After full reconstitution, B cells and myeloid 
lineage cells were found to be >90% donor-derived, while T cells were approximately 
60% donor-derived (see Appendix A). 
 
Results 
 To determine the relative contribution of IL-10 provided by non joint tissues, B6 
mice were infected and expression of IL-10 was assessed at day 7 and 14 of infection in 
the spleen, liver, heart, ear, and in the skin surrounding the tibiotarsal joint.  IL-10 
transcripts were detected in all tissues except the ear at day 14 of infection (Figure 3.1).  
While the spleen and liver likely represent major sources of IL-10 as whole tissues, 
	   92	  
infection-induced expression of IL-10 transcripts was not robust.  In contrast to these 
findings, both the heart and skin from the ankle joint displayed robustly induced IL-10 
transcript expression relative to uninfected controls, and represent regions of highly rich 
IL-10 expression at 2 weeks of infection (Figure 3.1).   
 Previous experiments utilizing macrophages derived from both arthritis resistant 
B6 mice and arthritis susceptible C3H mice demonstrated an unequal ability to produce 
IL-10 (16).  In addition to limited IL-10 production, C3H macrophages also produced 
higher quantities of pro-inflammatory cytokines (16).  Finally, microarray analyses of 
infected joint tissue failed to demonstrate induction of IL-10 in arthritis-susceptible C3H 
mice, suggesting that a failure to produced IL-10 may account for the differences in 
arthritis severity seen in B6 and C3H mice (17).  Additionally, B6 and C3H mice lacking 
Toll-like receptor 2 (TLR2) developed considerably more severe arthritis than WT mice 
of their respective strains (20, 21).  Arthritis development in these mice has also been 
correlated to extremely high expression of the chemokines CXCL-9 and CXCL-10, as 
well as other interferon-inducible transcripts (20).  The robust induction of interferon-
inducible genes is also correlated to increased arthritis severity in both the C3H and B6 
IL-10-/- strains, with the latter strain also possessing robust induction of CXCL-9 and 
CXCL-10 (17).  Furthermore, macrophages stimulated with B. burgdorferi lipoproteins 
produced IL-10 in a TLR2-dependent fashion (21).  Therefore it was hypothesized that a 
failure to induce IL-10 expression in the arthritis susceptible C3H and B6 TLR2-/- mouse 
strains accounted for the increased arthritis severity in B. burgdorferi-infected mice.  To 






Figure 3.1.  Induced expression of IL-10 is highly enriched in the infected heart 
and skin at 2 weeks after B. burgdorferi infection.  RT-PCR analyses of selected tissues 
from uninfected mice, and B. burgdorferi infected mice at 1 and 2 weeks of infection.  
cDNA was prepared from tissues as described in Materials and Methods.  N=3 mice per 
timepoint.  Bars represent the mean fold change ± calculated S.E.M, which includes error 
associated with β-actin normalization, and fold change normalization.  Values were 
calculated by diving each value by the mean obtained from uninfected samples.  
Statistical significance is indicated by (*) or (**), and represents p values of p>.05 and 
p>.01, respectively from one-way ANOVA and the Bonferoni post test for pair-wise 
comparison.    
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 test this hypothesis, B6, C3H and B6 TLR2-/- mice were infected with B. burgdorferi, 
and IL-10 expression in the skin (an IL-10-rich tissue) was quantified by RT-PCR at 7 
and 14 days of infection, with the understanding that a failure to produce IL-10 in the 
skin (both skin from the inoculation site and the skin from the ankle joint) would be 
correlated to increased arthritis severity in both the C3H and B6 TLR2-/- mouse strains.   
 In skin taken from the inoculation site, IL-10 expression peaked at 7 days of 
infection in B6 and C3H mice, and receded by 2 weeks of infection in B6, C3H, but was 
elevated in B6 TLR2-/- mice (Figure 3.2).  The fact that IL-10 expression was at similar 
levels at all time points between B6 and C3H strains suggests that C3H mice are not 
incapable of producing IL-10.  Furthermore, the induction of IL-10 in the skin is not 
dependent on B. burgdorferi lipoproteins signaling through TLR2, as IL-10 expression 
was present in the skin of TLR2-/- mice.  Interestingly, in skin samples from the 
inoculation site of B6 and C3H mice, IL-10 expression reflected the presence of B. 
burgdorferi in the tissue, which returned to low levels by 2 weeks of infection.  In 
contrast, B. burgdorferi 16s rRNA was easily detected in samples from TLR2-/- mice at 2 
weeks of infection (Figure 3.2).  Similar findings were obtained in skin surrounding the 
ankle joint, with comparable levels of IL-10 expression between B6, C3H, and B6 TLR2-
/- mice, however, unlike the results obtained from skin from the inoculation site, IL-10 
expression was only detected at 2 weeks of infection at this more distant site (Figure 3.2).  
As in skin samples taken from the inoculation site, IL-10 expression in skin from the 
ankle joint also reflected the presence of spirochetes (Figure 3.2-D).  Taken together, 
these data demonstrate that the arthritis susceptible C3H strain in perfectly capable of 
producing IL-10 at levels comparable to that seen in B6 mice, which suggests IL-10  








Figure 3.2.  IL-10 Expression in skin from infected B6, C3H, and B6 TLR2-/- mice 
correlates to the presence of B. burgdorferi.  RT-PCR analyses of skin from either the 
site of inoculation, or from around the tibiotarsal (ankle) joint.  Graphs on the left column 
display IL-10 transcripts over time, while graphs on the right column show the presence 
of B. burgdorferi 16s rRNA over time.  N=3 mice per group for each time point.  Bars 
represent the mean expression normalized to β-actin ± S.E.M. 
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production is not a differentiating factor between B6 and C3H mice, consistent with 
published findings (22).  Furthermore, the increased arthritis severity seen in B6 TLR2-/- 
mice is not due to an inability of these mice to produce IL-10 during B. burgdorferi 
infection.   
In IL-10-/- mice, B. burgdorferi infection results in increased arthritis severity and 
a profound induction of interferon-induced transcripts, not present in WT B6 mice.  The 
demonstration that skin from the ankle joint was enriched for IL-10 expression 
highlighted a need to characterize the cellular source of IL-10.  To determine if the source 
was hematopoietic in nature, radiation chimeras were constructed by lethally irradiating 
IL-10-/- mice (Ly5.1-), followed by transplantation of WT, Ly5.1+ splenocytes.  The 
efficiency of engraftment over time is shown in Appendix A.  At 12 weeks after 
transplantation, chimeras and control mice were infected with B. burgdorferi, and IL-10 
transcripts were quantified by RT-PCR at 2 weeks of infection.  In the skin from the 
ankle joint, IL-10 expression was detected at high levels in the skin, and was similar 
between unirradiated B6 mice and Ly5.1→IL-10-/- chimeras, suggesting a hematopoietic 
source of IL-10 in the skin of B. burgdorferi infected mice (Figure 3.3).  Interestingly, the 
presence of IL-10 in the skin also reflected higher levels of B. burgdorferi 16s rRNA, 
suggesting that leukocyte-derived IL-10 permits a higher bacterial burden in the skin 
(Figure 3.3).   The ability of IL-10 to suppress the expression of IFN-γ, and the 
interferon-inducible transcripts CXCL-9 and CXCL-10 was also assayed by RT-PCR.  
Expression of both CXCL-9 and CXCL-10 was significantly reduced in Ly5.1→IL-10-/- 
chimeras, as compared to control chimeras transplanted with autologous, IL-10-/- 
splenocytes.  Together, these data support the conclusion that a hematopoietic source of  









Figure 3.3.  A hematopoietic source of IL-10 regulates expression of interferon-
inducible transcripts in the skin.  RT-PCR analysis of ankle skin at 2 weeks after 
infection with B. burgdorferi from WT B6 (N=4), B6 IL-10-/- (N=4), WT LY5.1→IL-10-/- 
chimeras (N=4), and IL-10-/-→IL-10-/- chimeras (N=3).  Expression of IL-10, IFN-γ, 
CXCL-9, CXCL-10, and B. burgdorferi 16s rRNA was normalized to β-actin.  The term 
‘ND’ indicates that IL-10 transcripts were not detected.   
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IL-10 limits expression of pro-inflammatory interferon-inducible genes in the skin of B. 
burgdorferi infected mice, similar to what was observed for joint tissue.  To further 
characterize the cellular source of IL-10 in the skin of infected mice, a kinetic analysis of 
IL-10 expression was performed using the ‘tiger’ IL-10 reporter mouse strain.  These 
mice contain an IRES-GFP reporter cassette in the 3’ UTR region of the IL-10 gene (23).  
These mice were infected with B. burgdorferi, and ankle skin from infected tiger mice 
was harvested at 7, 11, and 14 days of infection.  As in the previous chapter, which 
identified F4/80+ macrophages and CD4+ T cells as the primary sources of IL-10, these 
cell types were also the only cell types associated with IL-10 (GFP) expression in the 
skin from the ankle joint.  Indeed, numerous CD11c+ cells, which broadly labels dermal 
dendritic cell subsets and epidermal Langerhan’s cells, were detected in skin samples, 
however, none were positive for GFP (data not shown).  GFP (IL-10) was not detected in 
uninfected mice, nor was it found at 7 days after infection.  However, as was seen in joint 
tissue, at day 11 of infection, there was a robust infiltration of both CD4+ T cells and 
F4/80+ macrophages (Figure 3.4A, B).  As a population, IL-10 (GFP)+ CD4+ T cells were 
at a higher frequency than were macrophages, although there were more total IL-10 
(GFP)+ macrophages than there were CD4+ T cells (Figure 3.4A, B).  Additionally, the 
mean fluorescence intensity for IL-10 (GFP) appeared to be higher in T cells than in 
macrophages, as observed in the joint (Chapter 2, Table 2.1).  Interestingly, the frequency 
and total number of IL-10 (GFP)+ CD4+ T cells decreased at day 14 of infection, whereas, 
both the frequency and total number of IL-10 (GFP)+ macrophages increased from day 11 
of infection to day 14 of infection (Figure 3.4A, B). 







Figure 3.4.  CD4+ T cells and macrophages are the major sources of IL-10 in the 
skin of B. burgdorferi-infected mice.   Control and infected tiger mice (N=3 per group) 
were analyzed for IL-10 (GFP) producing CD4+ T cells and macrophages in skin tissue 
from the joint.  Flow cytometry analysis of IL-10 expression in skin CD4+ TCR-β+ T cells 
from uninfected mice, at day 7, day 11, and 14 of infection (A-top).  Flow cytometry 
analysis of IL-10 expression in skin F4/80+ macrophages from uninfected mice, at day 7, 
day 11, and day 14 of infection (A-bottom).  Total skin CD4+ TCR-β+ T cells and total 
IL-10 (GFP)+ CD4+ TCR-β+ T cells (B-top).  Total skin F4/80+ macrophages and total IL-
10 (GFP)+ macrophages (B-bottom).  
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Discussion 
 Initial studies in B. burgdorferi-stimulated macrophages derived from arthritis 
susceptible C3H mice and arthritis resistant B6 mice comparing cytokine production, and 
found increased production of pro-inflammatory cytokines and nitrite among the arthritis 
susceptible strain.  Additionally, macrophages from the arthritis resistant B6 strain 
produced much higher levels of IL-10 than C3H-derived macrophages (16).  Previous 
microarray analyses of infected joint tissue from these two strains also revealed a robust 
interferon-inducible response that correlated to increased arthritis severity in C3H mice.  
A similar interferon-induced profile was also observed in B6 IL-10-/- mice.  Finally, no 
induction of IL-10 transcripts were observed in the infected joint tissue of C3H mice (17).  
With the demonstration that B. burgdorferi lipoproteins induce IL-10 production in 
macrophages by signaling through TLR-2, that B6 and C3H mice lacking Toll-like 
receptor 2 (TLR-2) developed considerably more severe arthritis than WT mice of their 
respective strains, and that arthritis development in these mice has also been correlated to 
extremely high expression of interferon-inducible transcripts, IL-10 was a prime 
candidate for explaining differences in arthritis severity among B6, C3H and TLR-2-/- 
mouse strains (20, 24).  The finding that IL-10 expression was robustly induced in the 
skin from the ankle joint allowed the formation of the hypothesis that IL-10 expression 
was reduced or absent in the skin from infected C3H and B6 TLR-2-/- mice.  RT-PCR 
analysis of infected skin derived from infected B6, C3H, and B6 TLR-2-/- mice 
demonstrated similar expression levels of IL-10, suggesting that signaling through TLR-2 
is not necessary for IL-10 induction in the skin.  Interestingly, the infected joints of TLR-
2-/- mice have been reported to contain a high number of T cells, which could be a major 
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source of IL-10 in the skin of TLR-2-/- mice.  Production of IL-10 by macrophages 
stimulated with B. burgdorferi lipoproteins was shown to be dependant on TLR2 
signaling, although IL-10 production was only partially reduced when macrophages were 
stimulated with sonicated B. burgdorferi (21).  This suggests that cells of the innate 
immune system are capable of producing IL-10 through TLR-2-independent pathways, 
thus the full measure of IL-10 expression in the skin is likely due to enhanced T cell 
produced IL-10, with a smaller contribution by macrophages.  The finding that 
expression of IL-10 was similar in skin from B6 and C3H mice further indicates that a 
failure to produce IL-10 is not the reason for differing arthritis phenotypes between B6 
and C3H mice.  This conclusion is consistent with a report that showed retroviral delivery 
of exogenous IL-10 failed to reduce arthritis severity in infected C3H mice (22).  
Additionally, none of the QTL identified by genetic linkage analysis between B6 and 
C3H intercross population contained the il10 gene (25). 
 A variety of cell types are capable of producing IL-10, including components of 
both the innate and adaptive immune response and other cell types associated with tissue 
function and vasculature (14).  In these studies, two approaches were employed to link 
IL-10 to its cellular source in the infected skin.  Both radiation chimeras and an IL-10 
reporter mouse demonstrated that leukocytes were the sources of IL-10 expression in the 
infected skin.  Furthermore, both CD4+ T cells and F4/80+ macrophages were found to 
express IL-10 in infected and skin tissues with comparable contributions of the detectable 
GFP reporter.  The infiltration of these IL-10 producing cells was first detected at 11 days 
after B. burgdorferi infection, similar to what was seen in the joint (Chpater 2).  Similar 
to what was found for IL-10 (GFP) expressing cells in the joint tissue, the GFP MFI was 
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greater in CD4+ T cells than in macrophages within the infected skin tissue.   
 B. burgdorferi induced of IL-10 by cells of both the innate and adaptive immune 
system is beneficial to both the spirochete and the host.  IL-10 produced by the host 
dampens the inflammatory response that would otherwise cause more severe tissue 
damage, resulting in pathology such as arthritis.  The benefit to the spirochete is that, in 
the presence of IL-10, the bacteria are more able to infect the host, and reach greater 
densities in the tissue (16, 22).  Because the skin plays a central role in both the 
transmission of spirochetes through the bite of infected ticks, and the acquisition of B. 
burgdorferi by feeding ticks, the induction of IL-10 is a possible mechanism utilized by 
the spirochete, to ensure its own propagation and survival (2).   
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Overview 
 
Interleukin-10 is a potent anti-inflammatory cytokine with pleiotropic activity.   
As in other infection models with the IL-10-/- mouse, the heightened inflammatory 
response to Borrelia burgdorferi permitted in the absence of IL-10 results in 5-to 10-fold 
fewer bacteria in the joint tissue, but infection result in a higher degree of lesion severity. 
Thus, a unique feature of this model is the observation that very low levels of bacterial 
antigens are capable of triggering an exuberant inflammatory response.  Previous 
microarray analyses of infected joint tissue from IL-10-/- mice demonstrated an enhanced 
expression of pro-inflammatory cytokines, most notably IFN-γ.  In the absence of IFN-γ 
signaling, arthritis is ameliorated in IL-10-/- mice, but mice harbored more spirochetes in 
their joint tissue.  Thus, the phenotypes associated with IL-10 deficiency are dependent 
on IFN-γ, and labels this pro-inflammatory cytokine as the primary target of IL-10 during 
arthritis development.  Because of the relationship between these two cytokines, the focus 
of this dissertation was to characterize the cellular sources of the anti-arthritic IL-10, and 
the pro-arthritic IFN-γ.  Utilizing an IL-10 reporter mouse, CD4+ T cells and 
macrophages were shown to be the primary sources of IL-10 within the infected joint and 
skin tissues, linking these cell types to an anti-arthritic activity.  Furthermore, enrichment 
of IFN-γ transcripts were found in NK cells and CD4+ T cells isolated from the joint 
tissue in infected IL-10-/- mice, formally linking these cells types to a pro-arthritic 
activity.  The finding that CD4+ T cells are capable of both promoting and suppressing 
arthritis development illustrates the importance of a highly regulated inflammatory 
response to limit tissue damage during the host response to invading pathogens. 
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Role of IFN-γ in Lyme Arthritis 
The role of IFN-γ in Lyme disease has long been a topic of debate.  In human 
patients, early production of IFN-γ in the EM lesion is thought to be beneficial to the host 
(1, 2), but in the late stages of disease, IFN-γ is thought to be associated with pathologies 
such as arthritis (3-5).  TH1 polarized CD4+ T cells have been postulated to the primary 
source of the late, pro-arthritic IFN-γ, although γ/δ T cells have also been found in Lyme 
arthritis patients (6-8).  Interestingly, the production of IFN-γ in Lyme arthritis patients is 
most prominent among those with post-treatment Lyme disease, where high levels of 
IFN-γ were found the synovial fluid or arthritis joints after antibiotic therapy (5).   
As discussed in Chapter 1, CD4+ T cell polarity in murine Lyme arthritis, 
particularly, the TH1 polarized subset, has thoroughly been examined in inbred strains of 
mice.  Although early studies using IFN-γ-neutralizing antibody reported reduced ankle 
swelling in B. burgdorferi-infected C3H mice, these reports were not repeated in 
subsequent studies using a similar method, nor using C3H IFN-γ-/- mice (9, 10).  A key 
component in this discrepancy is the lack of histopathological assessment of arthritis in 
the early studies (11).  In addition to the finding that IFN-γ was not required for arthritis 
development, additional findings have shown that this cytokine is also not required for 
arthritis resistance, nor is it necessary for the normal host defense against B. burgdorferi 
(9, 12).   
Previous gene expression analysis of joint tissue from B. burgdorferi -infected 
mice revealed an interferon-inducible response that correlated to increased arthritis 
severity in C3H and B6 IL-10-/- mice (13).  While this response was early (1 week of 
infection), and evanescent in C3H mice, it was delayed (2 weeks) and sustained (4 
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weeks) in B6 IL-10-/- mice.  Importantly, only the IL-10-/- mouse displayed induced 
expression of any interferon gene, with IFN-γ transcripts increased by 16- and 22-fold at 
2 and 4 weeks of infection, respectively (13).  Further analyses of B6 IL-10-/- mice 
revealed high concentrations of IFN-γ in the serum at 2 weeks of infection.  Taken 
together, the localized (joint) and systemic (serum) IFN-γ responses led to the hypothesis 
that IFN-γ was driving arthritis development in B6 IL-10-/- mice.  To test this hypothesis, 
B6 IL-10-/- mice were injected with PBS, a control antibody, or IFN-γ-neutralizing 
antibody over a 4-week infection with B. burgdorferi.  IL-10-/- mice treated with the anti- 
IFN-γ, but not PBS or control antibody, developed significantly less severe arthritis as 
assessed by ankle swelling and histopathology.  A major finding in this dissertation is 
that IFN-γ promotes arthritis development in B6 IL-10-/- mice, and suggests that the 
dysresulation of IFN-γ, whether by lack of IL-10 or some other mechanism, has the 
potential to promote the development of Lyme arthritis.  Thus, while former murine 
models of Lyme arthritis were unable to link IFN-γ to Lyme arthritis development, the 
IL-10-/- mouse provides an opportunity to measure the arthritic potential of this cytokine.   
Production of IFN-γ during B. burgdorferi infection has been observed both in 
vitro and in vivo for multiple mouse strains and cell types, as well as in human PBMC’s 
(2, 14, 15).  In an effort to identify possible cellular sources of IFN-γ, single cell 
suspensions of joint tissue were prepared from infected B6 and B6 IL-10-/- mice, and 
were analyzed by flow cytometry.  Among the populations found within the infected joint 
previously associated with IFN-γ production were NK cells, NKT cells, and α/β T cells, 
which were later found to consist primarily of CD4+ T cells (14, 16-18).  Depletion 
studies in B. burgdorferi-infected IL-10-/- mice indicate that CD4+ T cells, but not 
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NK/NKT cells, are responsible for the high levels of IFN-γ in the serum of infected IL-
10-/- mice.  Expression of interferon-inducible transcripts in the infected joint was not 
significantly reduced following NK/NKT cell depletion, and only a modest reduction in 
expression was observed following CD4+ T cell depletion.  This finding suggested either 
an incomplete depletion of target cell populations in the joint, or the possibility that 
multiple cell types produce IFN-γ within the infected joints of IL-10-/- mice.  To address 
the latter issue, an assay was designed where NK cells, NKT cells, and CD4+ T cells were 
sorted from single cell suspensions of joint tissue from infected IL-10-/- mice, followed by 
RT-PCR quantification of IFN-γ transcripts from the sorted fractions of cells.  
Enrichment of IFN-γ transcripts above unfractionated controls was observed in the NK 
cell and CD4+ T cell fractions, but not in the NKT cell fraction of sorted cells.  This 
suggests that NKT cells do not have an IFN-γ-mediated pro-arthritic activity in the joint 
tissue of IL-10-/- mice.  An important distinction between this study and previous studies 
seeking to determine cellular sources of IFN-γ is that previous studies measured IFN-γ 
production in cells re-stimulated in vitro or observed missing effects of IFN-γ signaling 
after cellular depletion (7, 10, 16, 19-22).  The current study directly linked IFN-γ mRNA 
to NK cells and CD4+ T cells by sorting these populations directly from the infected joint 
tissue of IL-10-/- mice, followed by RT-PCR quantification of IFN-γ mRNA transcripts.  
Interestingly, NKT cell have been reported to have an anti-arthritic activity in the BALBc 
mouse strain (17).  In addition, NKT cell-derived IFN-γ was also linked to the 
suppression of Lyme carditis (16).  The perceived contradiction that IFN-γ promotes 
pathological development in one tissue (joint), but prevents it in another (heart), is easily 
explained by the high expression of IL-10 in the infected heart (Chapter 3).  This suggests 
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that production of IFN-γ may cause excessive tissue damage only if it is improperly 
regulated.   
Signaling of IFN-γ through its receptor results in the transcription of multiple 
interferon-inducible genes.  Two of these genes, Cxcl9 and Cxcl10 were among the most 
highly induced transcripts in the joint tissue of B. burgdorferi-infected IL-10-/- mice.  
These chemokines signal through CXCR3, which is expressed on T cells, NK cells, and 
monocytes (23).  Both Cxcl9 and Cxcl10 were initially characterized as IFN-γ inducible 
genes.  Interestingly, expression of both of these chemokines was significantly 
diminished in B. burgdorferi-infected IL-10-/- mice injected with the IFN-γ-neutralizing 
antibody.  With the understanding that arthritis is driven by IFN-γ, and the induction of 
CXCL-9 and CXCL-10 is dependent on IFN-γ, there is likely a positive feedback loop 
that begins with early production of IFN-γ, followed by the production of CXCL-9 and 
CXCL-10 by IFN-γ-responsive cells.  These chemokines recruit NK cells and possibly T 
cells to the infected joint, whereon they produce more IFN-γ, and thus, begin the cycle 
anew.  The finding that IFN-γ, CXCL-9, and CXCL-10 were present at high level in the 
synovial fluid of patients with post-treatment Lyme arthritis suggests this feedback loop 
may also be present in humans, as does not require a high burden of antigen to develop, 
as antibiotic therapy is designed to eradicate the bacteria.  Thus, the low antigenic 
burden, high level of IFN-γ, CXCL-9, and CXCL-10 in B. burgdorferi-infected IL-10-/- 
mice closely resembles the symptoms associated with human post-treatment Lyme 
disease. 
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Induction of IL-10 in During B. burgdorferi Infection 
Initial studies in B. burgdorferi-stimulated macrophages derived from arthritis-
susceptible C3H mice and arthritis-resistant B6 mice compared cytokine production, and 
found increased production of pro-inflammatory cytokines and nitrite among the arthritis 
susceptible strain.  Additionally, macrophages from the arthritis resistant B6 strain 
produced much higher levels of IL-10 than C3H-derived macrophages (24).  Previous 
microarray analyses of infected joint tissue from these two strains also revealed a robust 
interferon-inducible response that correlated to increased arthritis severity in C3H mice 
(13).  A similar interferon-induced profile was also observed in B6 IL-10-/- mice.  Finally, 
induction of IL-10 transcripts was not observed in the infected joint tissue of C3H mice 
(13).  With the demonstration that B. burgdorferi lipoproteins induce IL-10 production in 
macrophages by signaling through TLR-2, that B6 and C3H mice lacking Toll-like 
receptor 2 (TLR-2) developed considerably more severe arthritis than WT mice of their 
respective strains, and that arthritis development in these mice has also been correlated to 
extremely high expression of interferon-inducible transcripts, IL-10 was a prime 
candidate for explaining differences in arthritis severity among B6, C3H and TLR-2-/- 
mouse strains (25, 26).  The finding that IL-10 expression was robustly induced in the 
skin from the ankle joint allowed the formation of the hypothesis that IL-10 expression 
was reduced or absent in the skin from infected C3H and B6 TLR-2-/- mice.  RT-PCR 
analysis of infected skin derived from B6, C3H, and B6 TLR-2-/- mice demonstrated that 
all three of these strains are capable of IL-10 gene expression at similar levels from both 
the ankle skin, and skin taken from the inoculation site.  This finding is consistent with a 
report that showed retroviral delivery of exogenous IL-10 failed to reduce arthritis 
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severity in infected C3H mice, indicating the underlying mechanism for arthritis 
development in C3H mice is not regulated by IL-10 (27). 
 
Role of IL-10 in Lyme Arthritis 
The critical role of IL-10 in suppressing tissue specific induction of interferon-
inducible genes and Lyme arthritis development in B6 mice suggested that early and 
consistent local production of IL-10 would be necessary to suppress arthritis severity (13, 
24).  A variety of cell types are capable of producing IL-10, including components of 
both the innate and adaptive immune response and other cell types associated with tissue 
function and vasculature (28).  In these studies, two approaches were employed to link 
IL-10 to its cellular source in the infected joint.  Both radiation chimeras and the IL-10 
reporter mouse demonstrated that leukocytes were the sources of IL-10 expression in the 
infected joint and skin.  Furthermore, both CD4+ T cells and F4/80+ macrophages were 
found to express IL-10 in infected joint and skin tissues with comparable contributions of 
the detectable GFP reporter.  Interestingly, the GFP mean fluorescence intensity (MFI) 
among CD4+ T cells from the joint tissue of infected tiger reporter mice was significantly 
higher than in macrophages at 11 and 14 days of infection (Chapter 2, Table 1).  This 
signifies that T cells produce more IL-10 on a single cell basis than macrophages.  This 
observation has been reported elsewhere, and the differences likely represents differing 
upstream signaling events that culminate in IL-10 gene expression (29).  Indeed, much 
data suggests that TLR signaling pathways in macrophages induce transcription factors 
such as NF-κB, C/EBP, and others to bind enhancer regions within the IL-10 promoter 
region (30-35).  In CD4+ T cells, IL-10 production is dependent on TCR signaling which 
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culminates in the activation and binding of c-Jun, among other transcription factors, to 
the IL-10 promoter (29).  Additionally, multiple DNaseI hypersensitivity sites have been 
identified within the IL-10 locus, but few of these enhancer containing regions are shared 
between CD4+ T cells and macrophages (29).  Thus, differences in the magnitude of IL-
10 expression between macrophages and CD4+ T cells during B. burgdorferi infection are 
hypothesized to be due to a unique usage of transcription factors, and epigenetic markers 
associated with cell lineage differentiation.  The finding that there are more IL-10 (GFP)+ 
macrophages present in the infected joint, especially at 14 days after infection suggests 
that, while CD4+ T cells produce more IL-10 on an individual basis, the overall 
contribution by both populations is comparable.  Although the subset of CD4+ T cell 
responsible for IL-10 production was not indentified in this study, we suspect 
involvement of TH2, Treg, or ever the newly identified Tr1 subset of CD4+ T cells.  The 
finding that FoxP3+ Treg cells in the joint were significantly fewer than the total IL-10-
producing CD4+ T cells suggested that the CD4+ T cell subset(s) responsible for IL-10 
expression consist of many non-Treg cells.  The peak of IL-10 expression by CD4+ T cells 
in the joint and surrounding skin occurs at 11 days after infection, and prior to the 
development of arthritis.  This suggests that IL-10 has a dampening effect on localized 
inflammation, and serves to prevent pathological development, rather than to resolve it.  
Interestingly, no CD11c+ cells were found to express the GFP reporter in the skin and 
joint during B. burgdorferi infection of tiger mice, despite the high likelihood of dermal 
dendritic cells and Langerhans cells interacting with the invading spirochetes.  Dendritic 
cell subsets and Langerhans cells, both of which stain positive for the CD11c marker, 
have been postulated to have regulatory roles in other models of inflammation; however 
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any anti-inflammatory role filled by these cell types is independent of IL-10 during B. 
burgdorferi infection (36-39).   
The early suppressive effects of IL-10 are robust and pleiotropic, as they limit 
expression of interferon-inducible genes, pro-inflammatory cytokines, and cellular 
infiltrates into the joint through the regulation of IFN-γ-dependant and IFN-γ-independent 
pathways.  The primary function of IL-10 in arthritis development is to suppress 
expression of IFN-γ, which is required for arthritis development in IL-10-/- mice.  
Interestingly, the accumulation of macrophages in the joint tissue of infected mice was 3-
4 fold greater in IL-10-/- mice when compared to WT controls, but depletion of IFN-γ in 
IL-10-/- mice did not reduce the total number of macrophages in the infected joint.  This 
suggests that the robust macrophage infiltration of joint tissue in IL-10-/- mice is not a 
major component of arthritis development.  Interestingly, treatment of IL-10-/- mice with 
the IFN-γ-neutralizing antibody resulted in a modest increase in joint spirochetes.  With 
the understanding that macrophages are capable of B. burgdorferi phagocytosis in the 
absence of opsonizing antibody, and the fact that there are greater numbers of 
macrophages in the infected IL-10-/- joint, it is reasonable to conclude that the large 
populations of macrophages within the infected joints of IL-10-/- mice is responsible for 
the enhanced pathogen clearance seen in IL-10-/- mice, consistent with other findings (40-
42).  It is also likely that IFN-γ serves to maintain and influence the activation state of 
these macrophages, and that in the absence of IFN-γ signaling, these macrophages are 
less able to kill the invading spirochetes.    
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Differences in Lyme Arthritis Development Between 
C3H and B6 IL-10-/- Mice 
The finding that IFN-γ mediates arthritis development in B6 IL-10-/- mice 
highlights a critical difference in arthritis development between C3H and B6 IL-10-/- 
mice.  Whereas arthritis development in C3H mice is dependant on Type I interferon and 
occurs in the absence of IFN-γ, results from Chapter 2 demonstrate that IFN-γ is required 
for arthritis development in B6 IL-10-/- mice (9, 10).  Thus we conclude that both Type I 
and Type II interferon pathways can influence arthritis development, given the correct 
circumstances.  Although many of the downstream effectors are identical between Type I 
and Type II interferon signaling, the mechanisms for arthritis development between C3H 
and B6 IL-10-/- mice appears to be distinct.  Of interest was the previous finding that the 
addition of exogenous IL-10 via adenoviral delivery failed to suppress arthritis 
development in C3H mice (27).  This may reflect failure of IL-10 to regulate the Type I 
IFN pathway inherent in the C3H mouse, and further suggests that Type I IFN masks pro-
arthritic contributions of IFNγ in infected C3H mice (16, 21, 39).   It has often been 
though that maximal arthritis severity occurs in WT C3H mice.  Interestingly, C3H      
IL-10-/- mice developed more severe Lyme arthritis than their WT counterparts, 
suggesting that IL-10 regulates a previously unrecognized pro-arthritic pathway, which 
possibly involves IFN-γ.  This supports the observation that Lyme arthritis can occur via 
multiple mechanisms as assessed by genetic linkage analysis, where several loci have 
been implicated in Lyme arthritis development (43, 44).   
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The IL-10-/- Mouse as a Model of Persistent Lyme Arthritis 
Most human patients with Lyme arthritis and other late stage symptoms respond 
to antibiotic therapy, after which arthritis eventually resolves (45).  However, in some 
cases arthritis persists for many months after treatment designed to eradicate infection, 
suggesting that there is a subset of individuals that maintain a long-term inflammatory 
response in the absence of active infection (5, 45).  This condition has been termed 
“antibiotic-refractory Lyme arthritis” of “Post-Treatment Lyme Disease,” (46, 47).  
Although initial hypotheses sought to explain this phenomenon by infection-induced 
autoimmunity, the current study helps to elucidate the possibility that local immune 
response in the joint to the invading spirochetes is poorly regulated and results in 
sustained inflammation within the synovium (45).  In support of this hypothesis, studies 
in mice have reported that robust antibiotic therapy does not always eliminate B. 
burgdorferi from the tissues (48, 49).  A primary phenotype associated with the IL-10-/- 
mouse model of Lyme arthritis is that the heightened inflammatory response permitted in 
the absence of IL-10 results in 5-to 10-fold fewer spirochetes in the joint tissue (24, 27).  
Thus, a unique feature of this model is the observation that very low levels of antigen are 
capable of triggering an exuberant inflammatory response.  In IL-10-/- mice, this 
inflammatory response most notably consisted of highly expressed IFN-γ, and the IFN-γ-
inducible chemokines CXCL-9 and CXCL-10 at both 2 and 4 weeks of infection (13).  
Similarly, in human patients with antibiotic-refractory Lyme arthritis, the synovial fluid 
collected from arthritic joint contained high concentrations of IFN-γ, CXCL-9, and 
CXCL-10 (5).  In addition to these similarities, arthritis in IL-10-/- mice persists beyond 4 
weeks of infection, as ankle measurements taken at the peak of arthritis severity (4 weeks 
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of infection) did not differ significantly from measurements taken at 8 weeks of infection 
(Appendix B). 
The IL-10-/- mouse model provides a much-needed model for studying the role of 
IFN-γ in Lyme arthritis development, as well as a new model of persistent arthritis.  
While complete IL-10 deficiency represents an extreme example of dysregulated 
inflammation, a host of factors could influence a prolonged inflammatory response. 
Interestingly, a loss of function polymorphism in the human il10r1 gene has recently 
been reported (50-54), and is associated with risk for extra-pulmonary tuberculosis and 
rheumatoid arthritis (50, 53).  While it is unlikely that treatment-refractory Lyme arthritis 
patients possess these genetic polymorphisms, the end results among these patients and 
B6 IL-10-/- mice are similar, in the elevated expression of IFN-γ and IFN-γ-inducible 
chemokines, and possibly represent the result of an insufficient regulatory response. 
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RECONSTITUTION EFFICIENCY OF LY5.1→IL-10-/- RADIATION  
SPLENIC CHIMERAS 







Figure A.1 IL-10-/- mice (Ly5.1-) were lethally irradiated with the indicated dose 
of radiation, and transplanted with 2×107 splenocytes 24 hours later.  Control animals 
(one IL-10-/- Ly5.1- and one Ly5.1+ WT)  were not exposed to any radiation, but were 
used to indicate normal leukocyte numbers.  Engraftment of donor-derived (Ly5.1+) 
leukocytes was monitored at 2, 4, and 6 weeks following lethal irradiation by flow 
cytometry.  Donor-derived blood leukocytes were identified as Ly5.1+, while residual, IL-
10-/- leukocytes were identified as Ly5.1-.  Lineage markers used to define myeloid cells, 
B cells, and T cells, were CD11b, B220, and CD3ε, respectively.  Values for total cell 
numbers were calculated by multiplying the total leukocyte count by the frequency of 
each lineage.  Bars represent the mean ± S.E.M.  
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THE IL-10-/- MOUSE IS A MODEL OF SUSTAINED ARTHRITIS 






Figure B.1  Arthritis persist beyond 4 weeks in B. burgdorferi infected IL-10-/- 
mice.  Six week old B6 and IL-10-/- mice were infected with the clonal (N40) strain of  B. 
burgdorferi, or sham infection.  Immediately prior to infection, ankle measurements were 
obtained, and the value was subtracted from subsequent measurements to determine 
swelling.  Swelling values from uninfected mice represent normal growth patterns.  
Ankle measurements were assessed in a blinded fashion.  Points represent the mean 
change in ankle measurement ± S.E.M.  Statistical significance obtained by one-way 
ANOVA and the Bonferoni post test is indicated by (*) and (**), and represent p values 
of > 0.05 and > 0.01 respectively.  Ankle swelling at 8 weeks of infection was not 
significantly reduced or increased in infected IL-10-/- mice or B6 mice respectively.   
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